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ABSTRACT: 
Introduction: Ovarian hormones have long been known to affect the sensory 
information processing in brain. Brainstem Auditory Evoked Potential (BAEP) and 
Visual Evoked Potential (VEP) are simple non-invasive electrophysiological tests for 
hearing and vision assessment. Studies have shown mixed results regarding variation 
in auditory & visual neural conduction during different phases of menstrual cycle. 
Aims and Objectives: The present study is done to evaluate BAEP &VEP in normal 
healthy females during different phases of menstrual cycle. 
Material and methods: This cross sectional study was conducted among 80 young 
healthy female 1st year nursing students of age group 18-20years having regular 
menstrual cycle. After taking a detailed menstrual history & clinical assessment of 
hearing and vision, BAEP & VEP was recorded in menstrual phase (Phase 1), 
proliferative phase (Phase 2) & secretory phase (Phase 3) of menstrual cycle using 
RMS Aleron 401 EMG/NCV/EP system.The data are analyzed by one way ANOVA 
Posthoc test followed by Dunnet t test.  
Result: The absolute latencies of all the waves of the BAEP and VEP as well as the 
inter-peak latencies of BAEP waves showed a decrease in the proliferative phase with 
statistically significant decrease in wave V and inter-peak latencies III-V and I-V of 
BAEP waves and P100 latency of VEP wave. On the other hand, the absolute 
latencies of the various BAEP and VEP waves as well as the inter-peak latencies of 
BAEP waves in the secretory phase were increased with statistically significant 
increase in the same above wave latencies and inter-peak latencies of BAEP and VEP 
waves. The VEP amplitude and BAEP amplitude ratio showed an increase in 
proliferative phase as compared to secretory phase. 
Conclusion: The study showed that BAEP and VEP changes in the menstrual cycle 
phases are attributable to the ovarian hormones oestrogen and progesterone, which 
mainly modifies the central processing of auditory and visual neural conduction. 
Key words: Menstrual cycle, Brainstem Auditory Evoked Potential, Visual Evoked 
Potential, Oestrogen, Progesterone.  
 
1. INTRODUCTION  
Menstrual cycle is the cyclical changes that occurring in the body of a female 
after attainment of puberty. This cycle starts with menarche, which   is the beginning 
of her reproductive life and ends with menopause, where she completes her fertile 
period. It represents the periodic preparation of the reproductive system, so that the 
female can give birth to a baby.1  
The external manifestation of this attainment of puberty in a female is the 
monthly discharge of blood through the vagina called menstruation. This is actually a 
monthly cycle, as the word menstrual comes from a Latin word mensis, that is a lunar 
month of 28 days.2, 3 The average duration of menstrual cycle is 28 days starting from 
the first day of bleeding or the menstrual phase to the start of the next.1,4 The 
menstrual flow usually last for 3 to 5 days and the average blood loss during each 
cycle is about 30 ml. 1 
          The menstrual cycle is mainly divided into endometrial cycle, that mainly 
focus on endometrial changes during the cycle and ovarian cycle, that mainly 
concerned with ovarian changes during each cycle. Endometrial cycle consists of 
menstrual phase, proliferative phase and secretory phase. Ovarian cycle consists of 
follicular phase and luteal phase separated by ovulation in between the two.5 The 
dominant event that occurs in menstrual cycle is the release of mature ovum from the 
ovary called ovulation.6The main hormone secreted in the proliferative phase or the 
follicular phase of menstrual cycle is oestrogen and the main hormone secreted in the 
secretory phase or the luteal phase is progesterone.5 
 Menstrual cycle reflects  interplay between the ovary, the pituitary gland and 
the brain.5 These cyclical changes mainly focus on the reproductive tract for the 
fertilization and implantation of the fertilised ovum but it also influence different 
sensory modalities like vision, hearing, taste, touch, olfaction etc. Changes in gonadal 
hormones, especially oestrogen and progesterone have been suggested by many 
researchers, as the reason for change in sensory perception throughout the cycle.7 
Evoked potential responses (EPR’s) are indicators of functional integrity of 
sensory and cognitive pathways which are useful non invasive tool for 
neurophysiological research.8 Brainstem Auditory Evoked Potentials (BAEP), an 
objective test which helps to assess conduction of auditory impulses through the 
auditory pathway up to midbrain. It also helps to assess severity of hearing deficits 
and middle portion of brainstem function.9   These are very small electrical voltage 
potentials which are originated from brain in response to sound stimulus and can be 
recorded from the scalp.10 It consists of five or more distinct wave forms labelled with 
Roman numerals lto V.  Analysis of BEAPs consists of measuring the absolute 
latency, absolute amplitude, and inter peak latency (IPL) I-V, I-III and III–V waves.11   
All these parameters will show changes during different phases of menstrual cycle.  
Visual Evoked Potential (VEP) assess the conduction of visual signals from the 
optic nerve up to the visual cortex. VEP records the electrical potential difference 
from the scalp evoked by visual stimuli, such as alternating checker board pattern on a 
computer screen. It includes three waves namely P100, N70, N135.9, 11 The wave P100 
peak latency, its amplitude and duration are the most commonly used parameters for 
assessing VEP studies.11 The hormonal changes in menstrual cycle reflects changes in 
the above parameters.  
Various studies have showed that ovarian hormones modulate the conduction 
of sensory information in the brain. Throughout the menstrual cycle auditory and 
visual thresholds get varied systematically. The thresholds for olfaction, taste, touch, 
two point discrimination and perception of light have also been found to vary in 
different phases of  menstrual cycle.7 Menstrual cycle influences several clinical and 
neurological illness which may worse during the premenstrual phase. EEG also shows 
variation throughout the menstrual cycle. How hormonal variation influencing the 
cerebral physiology is still in controversy.12, 13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. HYPOTHESIS AND JUSTIFICATION 
HYPOTHESIS: 
Variations in the Oestrogen and Progesterone levels during different phases of 
menstrual cycle may affect the auditory and visual neural conduction. 
SCIENTIFIC JUSTIFICATION OF THE STUDY: 
It is a well-established fact that the varying levels of sex steroids in different 
phases of menstrual cycle affect the mood and cognition of a female. A study done on 
prepubertal and aged mice showed that throughout the central auditory system 
estrogen receptors are present and they suggest that by regulating the transcription of 
genes via their classical estrogen receptor pathway, estrogens directly affect the 
processing of hearing in humans. According to different studies oestrogen has 
neurotrophic and neuroprotective effects throughout the CNS. Therefore it is of 
importance to understand the physiological actions and underlying mechanisms of 
estrogens in hearing and vision in order to develop estrogen-based strategies to protect 
hearing and vision.14 
Various studies showed visual and auditory threshold variation in different 
menstrual cycle phases. 7 The gonadal hormonal action on central nervous system, 
especially in auditory and visual sensory perception can be assessed by evoked 
potential studies. This study will give awareness to the physician regarding the 
changes in BAEP and VEP during different phases of menstrual cycle while 
considering the normal values in female subjects.  BAEP and VEP also provide 
important diagnostic information regarding the functional integrity of auditory and 
visual pathways. Hence the present study is done to find the Auditory and Visual 
Evoked Potentials in young healthy females during different phases of menstrual 
cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
3. AIM AND OBJECTIVES: 
1. To evaluate Brainstem Auditory Evoked Potentials (BEAP) in normal 
healthy females during different phases of menstrual cycle. 
2. To evaluate Visual Evoked Potentials (VEP) in normal healthy females 
during different phases of menstrual cycle. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
4. REVIEW OF LITERATURE  
4.1. Menstrual cycle: 
4.1.1. Introduction: 
The regular cyclical changes that occurs in the reproductive system of a human 
female constitute the menstrual cycle.1 These cyclical changes occurs regularly for a 
period of about one month.15  It is regarded as the periodic preparation of female 
reproductive system for pregnancy, starting from sperm & ovum transport, 
fertilization & implantation.5 The most conspicuous feature is the shedding of uterine 
mucosa externally manifest as periodic vaginal bleeding (menstruation).1 Menarche is 
the term used to denote the first menstrual cycle.12 to 14 years is the usual age of 
menarche.15 
4.1.2 Duration of menstrual cycle: 
The length of the cycle averages at about 28 days, from the beginning of one 
menstrual cycle to the beginning of the next.1 The 1st day of vaginal bleeding is 
considered as the day 1 of menstrual cycle.1, 2   The duration of each cycle is never 
fixed in all females and the duration of all cycles is not same in one female. The cause 
for this is the menstrual cycle is frequently influenced by environmental, nutritional, 
psychological and social factors.15 
  
4.1.3 Historical review of menstrual cycle: 16, 17, 18 
 In 1971 Schally and Guillemin found out GnRH. 
 In 1672 Regnier de Graaf accurately described corpus luteum for the first time. 
 In 1977 Goodman and Hodgen found that in humans, the ovulation occurs 
alternately in both ovaries due to the action of progesterone on follicular 
dynamics.  
 In 1978 Belchetz found that the differential release of FSH and LH is related to 
the GnRH pulse frequency. 
 In 1980 Knobil found that an intricate neuroendocrine control system is 
responsible for the cyclical pattern of reproductive activity in females. 
 In 1982 Fritz and Speroff found that for continued follicular growth an 
estrogenic environment is essential.  
 In 1982 Goodman et al found that after the degeneration of corpus luteum of 
previous cycle, it takes about 5-7 days for the development of new follicle to 
become dominant follicle.  
 In 1984 Ferin et al found that the major site of action of estradiol is pituitary 
and that of progesterone and testosterone is hypothalamus. 
 In 1986 Handelsman and Swerdloff found that the hypothalamic and pituitary 
peptidases rapidly degrade GnRH. 
 In 1986 Kesner et al. found that almost coincidental release of LH along with 
electrical potential changes in arcuate neurons in monkey, on measuring the 
electrical activities of these neurons. 
 In 1989 Hayflick et al. found that the gene for pre-pro-GnRH is present on the 
short arm of chromosome 8.  
 In 1992 Wetsel et al. found that the release of GnRH can be modified by inputs 
from central nervous system, as these neurons are localized within the 
hypothalamus adjacent to other neuronal system. 
 In 1994 Rance et al. found that a group of 7000 neurons present in 
hypothalamus synthesize and secrete GnRH.  
 1996 Guo et al found that Bax protein, apoptotic effector enzymes like 
Caspase-2, Caspase-9, and Caspase-11are invoved in follicular atresia.  
 In 1997 Motta et al. found that by about 6 weeks of gestation the primordial 
germ cells proliferate and migrate to the genital ridge and then it is known as 
oogonia. 
 In 2000 Johnson and Everitt found that prior to ovulation the rising level of 
progesterone exert an inhibitory effect on estrogen positive feedback. This will 
result in attenuation of midcycle LH surge. They also found that just before 
ovulation the follicle will have a size of 20 mm. 
 In 2000 McGee found that to maintain a viable oocyte high level of estradiol 
and low androgen/estrogen ratio is needed whereas an androgenic environment 
favours oocyte degeneration. 
 In 2002 Richard et al found that PGE2 and PGF2α are required in regulating 
transcription genes like CAAT, an enhancer binding protein β which is 
essential for changes in follicle wall and contents during ovulation. 
 In 2002 Davis and Rueda found that one of the factor regulating luteolysis is 
the infiltration of  reactive oxygen species in corpus luteum. 
 In 2003 Cone et al. found that in late follicular phase the elevated level of 
estradiolupto 500pg/ml for 36 hours enhance the release of gonadotropins from 
pituitary. 
 In 2004 Boime et al. found that in peripheral circulation the half-lives of LH 
and FSH are 20 and 180 minutes respectively. 
 In 2004 Strauss and Williams found that in the corpus luteum, the principal site 
for estrogen synthesis is the granulosa cells as they express aromatase and the 
theca luteal cells synthesize androgen precursors like 17α-hydroxyprogesterone 
as they express 17α-hydroxylase and 17-20 lyase. 
 In 2005 Wojcik-GladyszandPolkowska found that at the time of ovulation 
neuropeptide Y will potentiate GnRH stimulated LH secretion and suggested 
that neuropeptide Y is involved in sensitizing the pituitary during LH surge. 
 In 2009 Rozell and Okrainetz found that follistatin plays an important role in 
conversion of estradiol producing granulose cells of dominant follicle to 
progesterone producing luteal cells of corpus luteum. 
 Marcello Marpighi coined the term corpus luteum from the words corpora 
(bodies) and lutea (yellow). 
  
4.1.4 Phases of menstrual cycle:   
Menstrual cycle actually involves cyclical changes in ovary & uterus. The 
follicular phase & the luteal phase separated by ovulation constitute the ovarian cycle. 
The menstrual, the proliferative and the secretory phase constitute the endometrial 
cycle.19 
4.2 The Ovary: 
4.2.1 Ovarian morphology: 
The ovary of an adult female is oval in shape with a width of 1.5 to 3 cm, a 
length of 2 to 5 cm and a thickness of 0.5 to 1.5 cm. Ovary weighs between 5 and 10 
grams during the reproductive years. It consists of outer cortical region made of 
follicles and germinal epithelium. Medullary region made of connective tissue, 
interstitial cells and myoid like contractile cells. Hilum contains nerves, lymphatics 
and blood vessels that enter the ovary.6 
4.2.2 Embryology of the ovary: 
Three major cellular sources from which ovary develop are primordial germ 
cells, coelomic epithelial cells and mesenchymal cells. From the endoderm of the yolk 
sac primordial germ cells develop and differentiate into the oogonia. From the 
coelomic epithelial cells granulose cells develop. From the gonadal ridge 
mesenchymal cells develop and it forms the ovarian stroma. During the sixth week of 
gestation the primordial germ cells migrate to the gonadal ridge, there they undergo 
successive mitotic divisions to form multiple oogonia.6 
4.2.3 Ovarian Cycle: 
The cyclical changes occurring in the ovary during each female sexual cycle 
constitute the ovarian cycle.20The ovarian changes in this cycle completely depends on 
the anterior pituitary hormones LH and FSH.4 
4.2.3.1 Phases of ovarian cycle: 
1. Follicular phase 
2. Luteal phase 
4.2.3.1. A. Follicular phase: 
It is otherwise called preovulatory phase. This phase begins with menstruation 
and ends with ovulation.15, 19 Average duration of this phase is 14 days in a 28 day 
cycle. Duration of this phase is the most variable part of menstrual cycle. This phase is 
considered as the proliferative phase of endometrial cycle.5The major event in this 
phase is the maturation of follicles a process called folliculogenesis.15The main 
hormone regulating this phase is estrogen.20 
Folliculogenesis : 
At birth the female child’s ovary contains primordial follicle made of ovum 
surrounded by single layer of granulosa cells. The ovum is kept at its prophase stage 
of meiotic division till puberty with help of oocyte maturation-inhibiting factor 
secreted by the granulosa cells. At the onset of puberty pulsatile secretion of 
gonadotropin-releasing hormone (GnRH) from hypothalamus triggers the release of 
gonadotropins, the LH and FSH secretion from anterior pituitary. This leads to the 
formation of primary follicle having additional granulose cell layers.4Then secondary 
follicle having primary oocyte surrounded by multiple layers of cuboidal granulosa 
cells and differentiated stromal cells called theca cells develop. These granulosa cells 
secrete follicular fluid rich in estrogen4,6and growth factors6 into the centre of the 
follicle creating a fluid filled space called antrum.4,5,6 FSH alone stimulate the growth 
of primary follicle up to the antral stage.4,5 The follicle is now named as tertiary or 
antral follicle.6 Rapid increase in follicular size due to the accumulation of antral fluid 
results in the development of  vesicular or Graafian follicle.6 
About 10-15 primordial follicles start maturing but one of the follicles grow 
rapidly to form dominant follicle by about 6th day of cycle and the others regress to 
form atretic follicles.1 In humans ,usually only one follicle will be selected as the 
dominant follicle from either ovary. The reason for the selection of only one follicle to 
become dominant follicle is uncertain, it is thought to be due to the ability of the 
follicle to secrete estrogen inside it as estrogen is required for final maturation.1 
Follicular diameter increases to 20 to 33 mm.5 
 
 
4.2.3.1. B.Ovulation: 
The process by which oocyte is released from the matured Graafian follicle of 
ovary into the abdominal cavity.5 
Mechanism of ovulation: 
Near the end of late follicular phase estradiol secretion increase rapidly from 
the dominant follicle. This raised level of estradiol produce a positive feedback effect 
on hypothalamus as well as anterior pituitary results in LH surge. This gonadotropin 
surge occurs when there is increase in estradiol  concentration of 200 pg/ml for 50 
hours in the blood.5 This will cause rapid swelling of Graafian follicle due to increased 
blood supply & diffusion of plasma into the follicular fluid., Stretching of follicular 
wall results in the formation of an avascular area (stigma) over the most convex point 
of the follicle, release of proteolytic enzymes (plasmin  and collagenase) & dissolution 
of follicular wall results in rupture and release of secondary oocyte from the mature 
follicle.20 
Indicators of ovulation: 15, 20  
1. Increase in basal body temperature (BBT): Daily recording of early morning 
oral temperature will shows about 0.5 º c increases in basal body temperature 
after ovulation due to the thermogenic action of progesterone. 
2. Fleeting lower abdominal pain: During ovulation the rupture of dominant 
follicle results in some bleeding into abdominal cavity which cause peritoneal 
irritation leading to short lived lower abdominal pain called mittelschmerz. 
3. Increase in vaginal discharge and spotting 
4. Spinnbarkeit: cervical mucus will be thinnest and its elasticity will be 
maximum at the time of ovulation so the cervical mucus collect at this time can 
be stretched to about 10 cm or more. This elastic nature of mucosa is named as 
spinnbarkeit. 
5. Fern test: Before ovulation when the cervical mucus is spread on a slide it 
shows an arborizing fern like pattern.This pattern will not appear after 
ovulation. 
6. Ultrasound scanning and laproscopic examination demonstrating ovum in the 
abdominal cavity confirms ovulation.  
7. Demonstration of LH surge: LH peak occurs just before ovulation. So the day 
of ovulation can be detected by daily estimating the plasma LH level in the 
periovulatory period. 
8. The day of ovulation can be retrospectively calculated by subtracting 14 days 
from the first day of preceding menstruation, as it is a constant phenomenon 
that menstruation will come after 14 days of ovulation. 
4.2.3.1. C.  Luteal phase: 
It is otherwise called postovulatory phase. This phase begins after ovulation 
and ends with starting of next menstruation. Average duration of this phase is 14 days. 
Duration of this phase is the most constant part of menstrual cycle. This phase is 
considered as the secretory phase of endometrial cycle.20The major event in this phase 
is the formation of corpus luteum. The main hormone regulating this phase is 
progesterone.5 
The follicle that ruptures during ovulation gets filled with blood & forms 
corpus hemorrhagicum. Then there occurs proliferation of remaining granulosa and 
theca cells. The blood clotted inside the follicle is replaced rapidly with yellowish, 
lipid rich luteal cells and then the follicle is called corpus luteum. Then the luteal cells 
started secreting estrogen and progesterone. Vascular endothelial growth factor is 
essential for the development of corpus luteum.1 
If pregnancy occurs corpus luteum persists and forms corpus luteum of 
pregnancy. If pregnancy does not occurs it begins to degenerate after 24th day of the 
cycle and is eventually replaced by whitish scar tissue called corpus albicans.1, 20 Thus 
on the 26th day of cycle, the hormones secreted from corpus luteum such as estrogen, 
progesterone and inhibin A will decrease to a lower level and feedback inhibition to 
the pituitary is removed leading to a raise in FSH & LH later, resulting in initiation of 
next ovarian cycle.20 
4.3 Endometrial cycle: 5 
 The cyclical changes in the endometrium due to the cyclical production of 
estrogen and progesterone from the ovary constitute the endometrial cycle.5 
4.3.1 Phases of endometrial cycle: 
 1. Menstrual phase (1st to 5th day) 
 2. Proliferative phase (6th to 14th day) 
 3. Secretory phase (15th to 28th day) 5 
4.3.1. A.  Menstrual phase: 
 If fertilization does not occurs, corpus luteum degenerates and the hormonal 
support of endometrium weans off. Lysosomal membrane of endometrial cells 
undergoes destabilization and proteolytic enzymes will be released due to the 
reduction of steroids. This causes lysis of endometrium. Prostaglandin F2 alpha 
production increases which leads to vasospasm and endometrial ischemia. Areas of 
focal necrosis develops, these coalesce result in sloughing of endometrium and 
menstrual bleeding.8 Superficial 2/3rd of the endometrium is sloughed off and the thin 
basal layer of about 2 mm thickness will be left behind.20 
Endometrial debris contains blood, sloughed off tissue, serous fluid, 
fibrinolysin and prostaglandins. Fibrinolysin causes liquefaction of the clotted blood 
inside the uterine cavity. 20 Usually the duration of the menstrual flow last for 3 to 5 
days. The blood lost in each cycle on an average is about 30ml.The loss of blood is 
mainly arterial, only 25% is of venous origin.1 
4.3.1. B.  Proliferative phase: 
 The proliferation of endometrium is the major event in this phase. Under the 
influence of estrogen endometrial epithelialisation occurs.5 Endometrial proliferation 
occurs and thickness increases to 8-10 mm just before ovulation.21 Endometrial glands 
lengthen and drawn out. Endometrial vascularity increased with the formation of more 
number of spiral arteries .Myometrial excitability increases in this phase.15 
4.3.1. C. Secretory phase: 
Under the influence of progesterone the uterine glands coiled and tortuous 
forming corkscrew shaped and vascularity of endometrium increases. 5 Spiral arteries 
become tortuous.Glandular cells store glycogen and starts secreting mucus and fluid in 
large quantities. These secretions contain glycogen, glycoproteins and glycolipids, 
which sustain and facilitate attachment of conceptus.Due to the effect of progesterone 
the rapid proliferation of endometrium slows down, mitotic activity reduced and the 
endometrial thickness decreases to 5mm.21 Endometrial veins form venous lakes and 
anastomosis. Myometrial excitability decreases in this phase.15 
Transforming growth factor beta 3, Betacellulin and neuregulin-1 alpha and 
beta plays an important role in secretory phase endometrial maturation.22 
4.4 Cyclical changes in the cervix: 15, 20 
 In proliferative phase- Increase in volume, elasticity and alkalinity of cervical 
mucus due to the influence of estrogen. 
 In secretory phase- Decrease in volume, elasticity and increase in thickness of 
cervical mucus due to the influence of prgesterone. 
4.5   Cyclical changes in the vagina: 15, 20 
 In proliferative phase- Vaginal epithelial cornification occurs due to the 
influence of estrogen. 
 In secretory phase- Vaginal epithelial proliferation and thick mucus secretion 
occurs due to the influence of progesterone.  
 
Figure1. Ovarian and uterine changes during the menstrual cycle.1 
 Figure 2: Approximate plasma concentration of gonadotropins and ovarian 
hormones during the menstrual cycle 4 
 
4.6 Hormones regulating menstrual cycle: 
 The cyclical changes in menstrual cycle is regulated by the hypothalamo-
hypophyseal-ovarian axis.5 
4.6.1 Role of hypothalamus: 
 Arcuate nucleus and preoptic area of hypothalamus secrete gonadotropin 
releasing hormone (GnRH) in a pulsatile manner into the anterior pituitary through 
hypohalamo-hypophseal portal system.20This will stimulate the gonadotrophs of 
anterior pituitary gland to release the gonadotropins namely FSH and LH.5 The GnRH 
release is influenced by estrogen, progesterone, ratio of FSH and LH, dopamine, 
endorphins, dark and light cycles operating through melatonin. 20 
4.6.2 Role of anterior pituitary: 
 In response to GnRH stimulation the anterior pituitary secrete Follicle 
Stimulating Hormone (FSH) and Luteinizing Hormone (LH).20 
4.6.2. A.   Follicle Stimulating Hormone 
 In the early part of follicular phase FSH secretion increases and then slowly 
declines. Along with the rise in LH there will be a rise in FSH secretion towards 
ovulation.15 
4.6.2. B. Luteinizing Hormone 
 LH secretion started increasing about a day before ovulation and reaches peak 
concentration at about 8-10 hours prior to ovulation.15 
4.7   Role of ovary: 
Ovary secrete gonadal hormones namely estrogen and progesterone in response 
to gonadotropin secretion from anterior pituitary. It also secrete inhibin and activin.5
  
4.7. A.  Estrogen : 
 They are C18 steroids secreted by the ovarian follicular granulosa cells, 
placenta, corpus luteum1and a minor quantity from adrenal cortex and testis.2017β-
estradiol, estrone and estriol are the naturally occurring estrogens.Aromatase (CYP19) 
enzyme which converts testosterone to estradiol and androstenedione to estrone is 
very important for its biosynthesis. The latter reaction also occurs in brain, fat, liver 
and muscle.1  
Its concentration starts increasing in the beginning of follicular phase, along 
with the growth of ovarian follicle. Then it rapidly raise from 8th day of the cycle and 
a peak concentration attained at about 48 hours before ovulation. This raise in 
estrogen cause LH surge by positive feedback mechanism resulting in ovulation. This 
is the major estrogen peak. A minor peak occurs 2 days after ovulation.15 
Steps of synthesis of estrogen: 
 In the follicular phase, cholesterol to androstenedioneconvertion in the theca 
cell is primed by LH. But it cannot convert androstenedione to estradiol as the theca 
cells lack the enzyme aromatase. Androstenedione diffuses to the FSH stimulated 
granulose cells where aromatase convert it into estradiol.5 
Metabolism: 
In the blood, two percent of estradiol occurs in free form, 60% bound to 
albumin and 38% to the gonadal steroid-binding globulin (GBG) .Estradiol, estrone, 
and estriol are converted to glucuronide and sulfate conjugates in the liver and 
excreted in the urine.1 
Mode of action: 
Estrogen binds with its nuclear estrogenreceptors  ERα and ERβ encoded by 
genes on chromosome 6 and 14 respectively. ERα receptor is present mainly in uterus, 
heart, liver and kidneys. ERβ reseptor is present mainly in ovaries, lungs,hemopoietic 
system , prostate, gastrointestinal tract,  and central nervous system (CNS).1This 
hormone receptor complex interacts with steroid-response elements on DNA results in 
new mRNA and protein synthesis.23Studies also demonstrate the non-nuclear ERs 
(membrane-associated ERs) can couple to second messenger system and generate 
rapid actions in the nervous system.24 
Physiological actions: 
1. Actions on female reproductive organs15,20 
 On ovary: Estrogen stimulates ovarian follicular growth as well as ovarian 
growth. 
 On fallopian tube: Estrogen increases fallopian tube motility by stimulating its 
smooth muscle contraction. 
 On uterus: It causes uterine endometrial proliferation during the follicular 
phase of mensrual cycle. 
 Along with progesterone it causes increase in uterine fluid secretion during the 
luteal phase of mensrual cycle. 
 It increases the uterine size and blood supply, uterine myometrial excitability 
and uterine sensitivity to oxytocin. 
 On cervical mucus secretion: It makes the cervical mucus clear, profuse and 
watery. These changes are more prominent at the time of ovulation.15 
 On vagina: It converts cuboidal vaginal epithelium to cornified squamous 
epithelium. 
 On external genitalia: It causes increase in size of clitoris, labia majora and 
minora.20 
2. Actions on breast15  
 It causes stromal tissue development in breast as well as increase in size of 
breast by deposition of fat. 
 It causes growth of ducts in breast as well as pigmentation of areola. 
3. Actions on development of secondary sexual characteristics15  
Estrogen causes development of female pattern of body configuration such as 
broad hips and narrow shoulders, wide carrying angle, high pitched voice, female 
escutcheon of pubic hair, less body hair and more scalp hair, growth of internal 
gentalia both in size and function. 
4. Actions on other endocrine organs15  
 It inhibits LH secretion by negative feedback effect and stimulates LH 
secretion before ovulation by positive feedback effect on anterior pituitary. It inhibits 
FSH and prolactin secretion. It stimulates adrenal androgen secretion. It increases 
angiotensinogen synthesis from liver and activates rennin-angiotensin system. It 
increases thyroxine –binding globulin synthesis.  
 5. Actions on CNS15,24 
 It cause a selective enhancement of the growth and differentiation of axons as 
well as dendrites in the developing brain, modulating neurotransmitter production and 
release, enzyme activity, membrane potential, dendritic arborization, and 
synaptogenesis . 
It affects the basal forebrain by regulating the cholinergic neurons that project 
to cerebral cortex and hippocampus, in where they play an important role in cognitive 
function. 
It enhances cerebral blood flow through various mechanisms, such as 
vasodilation mediated by production of nitric oxide synthaseregulation of coagulation 
and thrombolysis and reduction of blood total cholesterol and low-density lipoprotein. 
24 
It stimulates libido by activating limbic system and produces sexual behaviours 
by acting on suprachiasmatic area of hypothalamus. 15 
6. Actions on musculoskeletal system15 
 It inhibits osteoporosis and stimulates bone growth and determines the height 
of a female by causing epiphyseal closure. 
7. Actions on electrolytes and water balance15 
 It helps in increased absorption of water and salt by kidney tubules.  
8. Actions on lipid metabolism15 
 It lowers blood cholesterol level.  
9. Actions on sebaceous gland and skin1 
 It makes the sebaceous secretion more fluid there by prevent acne and 
comedone formation and makes the skin soft in texture.  
10. Action on blood vessel20  
It produces rapid vasodilation by local release of nitric oxide, prostaglandins E2 
and prostacyclin and produce antivasoconstrictor effect through inhibition of 
endothelin-1release. 
11. Nongenomic actions of estrogen1 
Its effects on neuronal discharge in the brain and, possibly, feedback effects on 
gonadotropin secretion are mediated by cell membrane receptors that appear to be 
structurally related to the nuclear receptors. These effects are produced by stimulating 
intracellular mitogen-activated protein kinase pathways. 
4.7. B.Progesterone 
 Progesterone is a C21 steroid secreted mainly by the corpus luteum, the 
placenta, and in minor quantities from the follicle, testes and adrenal cortex.1It is 
called non-hormone as it has no actions of its own.2 Following ovulation its 
concentration starts increasing and reaches a peak at about 4 to 5 days after ovulation. 
Towards the end of luteal phase, along with the regression of corpus luteum 
progesterone concentration declines to a lower level.15 
Metabolism: 1 
It is metabolized to pregnanediol in liver and excreted as glucuronide conjugate 
in urine. 
Mode of action: 1 
The stimulating effect of LH on progesterone secretion by the corpus luteum is 
due to activation of adenylyl cyclase and involves a subsequent step that is dependent 
on protein synthesis. 
Physiological actions:  
It acts on estrogen primed target organs. 2The uterus, the breasts, and the brain 
are the principal target organs of progesterone.1 
1. On uterus1, 2, 4 
 It cause secretory changes in the estrogen primed endometrium. 
 It decreases the intensity and frequency of uterine contractions. 
 On the myometrial cells it has antiestrogenic effect. So it decrease myometrial 
excitability, their spontaneous electrical activity and sensitivity to oxytocin It 
also increases the myometrial membrane potential. 
 It decreases the number of endometrial estrogen receptors and  cause increase 
rate of conversion of 17β-estradiol to less active estrogens. 
2. On breast1 
It causes differentiation of estrogen primed ductal tissue.It also stimulates the 
development of lobules and alveoli and during lactation it supports the secretory 
function of the breast. 
3. Onhypothalamo pituitary axis15  
In large doses it prevents ovulation by inhibiting LH secretion and potentiate 
the inhibitory effect of estrogen. 
4. On body heat production1, 2 
Progesterone is thermogenicand also its metabolites etiocholanolone and 
pregnanediol.This may be the reason for the increase in basal body temperature at the 
time of ovulation. 
5.On respiration1 
It stimulates respiration. In the luteal phase the alveolar PCO2 of females will 
be lower than that in males.  
6.On electrolyte balance1 
 Large doses of progesterone produce natriuresis by inhibiting the action of 
aldosterone on kidney. 
 
 
4.8. EVOKED POTENTIALS 
4.8.1. Introduction: 
In1987 Chiappa et al.,  defined evoked potential as the record of the electrical 
activity produced by groups of neurons within the spinal cord, brain stem, thalamus or 
cerebral hemispheres following stimulation of one or another specific system by 
means of visual, auditory, or somatosensory input.25 The source of these activities is 
probably the summation of the action potentials generated by the afferent tracts and 
the electrical fields or activities of the synaptic discharges or post-synaptic potentials 
on those tracts.26 Evoked potentials provide a measure of the function of sensory 
systems.27 
4.8.2.   Historical Reviews 9,25,26,28 
 DuBois Raymond - detected the changes in potentials as the impulse passed 
down the nerve trunk. 
 Richard Carton – conceived the idea that as the nerve impulse flows in and out 
of brain its passage might be detectable. He discovered electroencephalogram 
and the cerebral potential changes evoked by sensory stimulation especially 
with visual stimuli. 
 PravadichNeminsky – gave the first photograph of evoked potential recorded 
from cortex of a dog following stimulation of sciatic nerve. He also 
demonstrated that EEG could be recorded from an intact skull. 
 Dawson -employed the neuro-electric responses to sensory stimuli that can be 
readily and non-invasively recorded using averaging techniques (1947). 
 Adolf Beck – discovered the desynchronization of ongoing oscillatory activity 
on sensory stimulation, which is now recognized as alpha blocking of EEG. He 
found the positioning of electrodes which gave a response to light and a faint 
response to sound. 
 Larionov – done mapping the topographic centers of temporal cortex of a cat in 
response to tuning fork stimuli of different pitches in 1889. 
 Hans Berger named the spontaneous ongoing activity of the brain as “Das 
Elektrenkephalogram’ and in 1940 launched EEG as a clinical neurologic test. 
 
4.8.3. Clinical Utility Of Evoked Potentials (Eps) :26 
The clinical utility of evoked potentials (EPs) is based on their ability to: 
 Demonstrate abnormal sensory system conduction, when the history and/or 
neurological examination is equivocal 
 Reveal subclinical involvement of a sensory system (‘‘silent’’ lesions), 
particularly when demyelination is suggested by symptoms and/or signs in 
another area of the central nervous system 
 Help define the anatomic distribution and give some insight into 
pathophysiology of a disease process 
 Monitor changes in a patient’s neurological status. 
 EPs proved to be helpful in: 28 
a. Testing sensory functions when clinical examination is not reliable. 
b. Investigating purely subjective symptoms and detect whether they have an 
organic origin. 
c. Better assessing the causative mechanisms of neurological deficits and 
functional recovery. 
d. Monitoring cerebral functions when the patient’s condition is critical or at risk 
in the operating theatre or during intensive care. 
 
4.9. Brainstem Auditory Evoked Potentials (BAEPs) / Brainstem Evoked 
Responses (BSERs) / Auditory Evoked Potentials (AEPs) 29 
Auditory Evoked Potentials are first recognised in human 
electroencephalogram in 1939.30The brainstem auditory evoked potential (BAEP)is an 
objective electrophysiological method for assessing the auditory pathways from the 
auditory nerve to the brainstem.31These are potentials recorded from ear and vertex in 
response to a brief auditory stimulation.9 These potentials are produced with in the 
first 10 milliseconds of sound stimulus.11,32 Therefore it is considered as short latency 
potential.29,31 ABR is an early auditory evoked potential (AEP) and is not affected by 
sedatives  and general anaesthetics therefore this test is a useful tool for assessing non-
cooperative populations such as infants, young children and severe mentally retarded 
patients.33 AEPs are now widely used in audiology, neurology, neonatology and 
anaesthesiology.34 
 
 
It helps to assess: 9 
 Conduction through the auditory pathway up to the midbrain. 
 Middle portion of midbrain function. 
 Severity of hearing deficits in infants. 
 Hearing in very young children and uncooperative patients. 
4.9.1. Anatomical and physiological basis of BAEPs: 9 
The sound waves are transmitted from the external and middle ear to the  
inner ear. The inner ear consists of coiled cochlea containing organ of corti with the 
auditory receptors. The low frequency sounds affect the apical end of cochlea and 
high frequency sounds affect the basal end of cochlea. The amplitude of movement is 
directly related to the intensity of the acoustic signals. The stimulation of cochlea 
results in eighth nerve activity. The latency of eighth nerve discharge will be shorter 
from the basal compared to the apical end of cochlea. The eighth nerve is a bipolar 
neuron which is situated in the spiral ganglia, their dendrites go to hair cells and axons 
to the cochlear nucleus. The cochlear nucleus has three subnuclei namely, anterior 
ventral (AVCN), posterior ventral (PVCN) and dorsal cochlear nucleus (DCN) .The 
output of AVCN is through the ventral acoustic striae forming the bulk of trapezoid 
body to terminate in the superior olivary nuclei and inferior colliculus. The neurons in 
AVCN discharge at short latency to acoustic stimuli. The output of PVCN mostly 
goes through ventral and middle acoustic striae to terminate in superior olivary nuclei 
and inferior colliculus. Dorsal cochlear nucleus terminates in the superior olivary 
nucleus and contralateral inferior nucleus through dorsal striae. These neurons 
discharge at long latency to acoustic stimuli. The excitatory input from both ipsilateral 
and contralateral AVCN reaches the medial superior olivary nucleus. The lateral 
superior olivary nucleus receives excitatory input from ipsilateral AVCN and PVCN 
and inhibitory inputs from contralateral AVCN and PVCN via trapezoid body. From 
the olivary nuclei, the impulses travel to ipsilateral and contralateral lateral lemnisci 
and to the inferior colliculi. The olivary nuclei are the first site in the auditory 
pathways where the neurons are affected in a nonlinear manner to binaural 
stimulation.The impulse from inferior colliculi reach medial geniculate body and then 
to auditory cortex, that is superior temporal gyrus and upper bank of sylvian fissure 
including the frontal and parietal opercula. 
The orderly orientation of the neurons in dorsal cochlear, medial superior 
olivary, and lateral superior olivary nuclei results in summation of synaptic potentials 
to result in high amplitude electrical fields. The nuclei are connected by large 
myelinated fibre tracts and their synchronous discharge also generates cohesive 
voltage fields. 
4.9.2. Brainstem electrical activity and its correlation with BAEP 9, 31 
After 10ms of acoustic stimulation, a series of potentials generated 
corresponding to the sequential activation of peripheral, pontomedullary, pontine, and 
midbrain portion of auditory pathways. The acoustic nerve and brainstem auditory 
potentials are volume conduction to surface recording electrodes. At the vertex and 
earlobe, these form vertex positive and vertex negative waves, which are known as 
BAEPs. It consists of five to eight9 distinct   vertex positive waveforms which are 
labelled with Roman numerals. The BAEP waves I, III and V are the most visible and 
clinically more significant.31 
4.9.3. BAEP waves and their site of origin 9, 29, 30, 31 
Wave I- Acoustic Nerve (Eighth nerve) 
Wave II-Cochlear nucleus (Medulla) 
Wave III- Superior olivary nucleus (Pons) 
Wave IV- Lateral lemniscus (Pons)   
Wave V- Inferior colliculus (Midbrain)  
Wave VI- Medial Geniculate (Thalamus) 
Wave V- Auditory Radiation (Thalamocortical) 
 
 
 
 
 
 
 
 
 
Figure 3: BAEP waves and their site of origin 
4.9.4. Analysis of BAEPs 9, 11, 30 
The parameters measured for the analysis of BAEPs are: 
1. Absolute latency: It is measured in msec from peak of the respective waves. 
 Wave I: It is a prominent up-going peak in the ipsilateral ear recording 
channel. It is visible 1.4 ms after the stimulus. It is markedly attenuated or 
absent from the contralateral ear recording channel. 
Clinical significance: Absent in patients with peripheral hearing impairment. 
 Wave II: It appears as a small peak. It is more prominent in contralateral 
channel recording. 
 Clinical significance: Absent in cochlear nucleus lesion. 
 Wave III: It appears as a prominent peak which is followed by a prominent 
trough. In contralateral channel recording it appears smaller and earlier than the 
ipsilateral ear.  
Clinical significance: Absent in superior olivary nucleus lesion.  
 Wave IV: It appears as very small wave in the up going slope of wave V. 
Clinical significance: Absent in lateral lemniscus lesion. 
 Wave V: It is the most prominent peak appearing 5.5 ms after the stimulus.  It 
starts above the baseline and its trough is maximum below the baseline. In 
ipsilateral recording channel it may fuse with wave IV forming IV-V complex. 
It mainly derives from connections of the basal turn of the cochlea which 
subserves the reception. 
 Clinical significance: Absent in inferior colliculus lesion. 
2. Absolute amplitude: It is measured in µV from the peak of the wave to the bottom 
of the trough of wave. 
3. Interpeak latency (IPL): Commonest used IPLs in clinical practise are I-V, I-III, 
and III-V. 
I-V IPL: It is the difference in latency between wave V and I. It is a measure 
of conduction from proximal VIII nerve through pons to midbrain. Normal upper limit 
is 4.5 ms. Slightly shorter in young women and longer in older men. Normal right to 
left asymmetry should be less than 0.5 ms.It is prolonged in demyelination, ischemia, 
tumours, brain damage due to ischemia, degenerative disorders, etc. 
I-III IPL: It is is the latency difference between wave III and I. It measures the 
conduction from VIII nerve across subarachnoid space into the core of lower pons. 
Normal upper limit is 2.5 ms. Normal right to left asymmetry should be less than 0.5 
ms.  It is prolonged in- tumour or inflammation affecting proximal portion of VIII 
nerve,meningitis, subarachnoid hemorrhage, Guillain-Barre syndrome, 
cerebellopontine angle tumors, etc. 
III -V IPL:  It is the difference in latency between wave V and III. It measures 
the conduction from lower pons to midbrain.  Normal upper limit is 2.54ms. Normal 
right to left asymmetry should be less than 0.5 ms. 
4. Amplitude ratio of wave V/I:  Since wave I is generated outside the CNS and wave 
V inside, these can be compared to determine the relationship of expected signal 
amplitude. It can be expressed either as ratio or percentage. Normal ratio is between 
50% and 300%. Ratio less than 50% suggest central hearing impairment such as 
multiple sclerosis, hydrocephalous. Ratio higher than 300% suggests peripheral 
hearing impairment, high frequency in particular or a sensorineural type. The lower 
limit of wave V/I amplitude in full-term infants is 30%. The absolute latency and 
interpeak interval measurements are most widely used parameters clinically.31 
Table 1: Normal values of BAEP 9 
Wave (latency ms) Misra and Kalita(Mean ± SD) 
I 1.67± 0.17 
II 2.78 ±0.21 
III 3.65±0.22 
IV 5.0±0.30 
V 5.72±0.3 
VI 7.2±0.48 
I-III IPL 1.99±0.25 
III-V IPL 2.08±0.60 
I-V IPL 4.04±0.25 
   V/I Amplitude Ratio         : 0.5-1.3 35 
  
4.9.5. Factors affecting BAEP waveforms: 
 a. Technical factors25 
1. Stimulus intensity (click) 
On decreasing intensity by about 0.03 msec/dB the absolute latencies increase 
and amplitudes diminishes. 
2. Stimulus rate 
On increasing click rate the absolute latency of all BAEPs waves increases and 
amplitude of most of the waves decreases. At higher rates interpeak latencies increase 
slightly. 
3. Stimulus mode 
Binaural stimulation produces higher amplitude waves especially III, IV, V at 
all stimulus intensities than monoaural and binaural stimulation logically produces a 
higher V/I amplitude ratio than monoaural stimulation at a given stimulus intensity. 
4 Filter setting 
Filter settings affect relative amplitudes of BAEPs. 
5. Site of reference 
If reference electrode is kept on the contralateral ear II-III interpeak latency 
decreases and IV-V interpeak latency increases. 
 
b. Subject factors 25, 29 
1. Age: 
The absolute peak latencies of the BAEP waves mainly waves I, III, and V 
increase with an increase in age. In subjects aged 50 years and older the absolute 
latencies of Waves I, III, and V are 0.1 to 0.2 ms longer than young adults. The 
interpeak latencies (IPLs) of the waves I-III, III-V and I-V in the older age groups had 
an increased value as compared to that in younger individuals.27, 29, 33 
Females have shorter latency and higher amplitude compared to       males. I-V 
IPL is shorter by 0.1 ms in females compared to males, which may be due to higher 
internal body temperature, differences in the hormones, and shorter length of brainstem 
auditory pathway.9, 29 
2 .Body temperature: 11 
 The absolute latency and IPL are prolonged on lowering body temperature. The 
wave V latency will be slightly prolonged in individuals addicted to alcohol or 
barbiturates because these agents produce hypothermia. 
3. Hearing status: 11 
 Hearing impairment can alter the BAEPs, therefore, otoscopic examination, 
audiometry and hearing tests should be evaluated before conducting BAEP study.   
 A comparative study of Brain stem Auditory Evoked Potentials in 25 preterm 
and 25 full-term infants done by M.S Roopakala et al showed a prolongation in 
latency of wave V in preterm infants and suggested reason for this as retarded 
myelination of the central auditory pathway. They concluded that electrophysiological 
tests like BAEP could be used to assess neuronal maturation and myelinaton in 
preterm infants.36 
Auditory evoked potential study done by Maria Khatoon et al inDepartment of 
Physiology, Peoples College of Medical Sciences, Bhopal, India, in twenty five 
normoacoustic elderly subjects &  twenty five age and sex matched controls (young 
adults between 18-25 years age group) showed  prolonged wave III & wave V 
latencies in older adults as compared to the young adults . The interpeak latency I-III 
and I-V are also prolonged which suggest that aging process is central phenomenon.27 
A study done by Harinder J S et al., Government Medical College, Amritsar, to 
find the age and sex related changes in the brainstem auditory evoked potential in 150 
normal healthy subjects of different age groups (G1 = 15-29 years, G2 = 30-45 years, 
G3 = 46 years onwards), with a matched number of males and females in each group 
showed that the absolute latencies of the waves III, IV and V significantly increases 
and interpeak latency of the waves, I-III and I-V also increases with increasing age, 
thus suggested degenerative changes in the auditory pathway and synaptic delay.The 
latencies of the waves III, IV and V and interpeak latencies of the waves, I-III, I-V 
and III-V are significantly increased in males as compared to the females. Thus 
suggests age and sex have an effect on latency and interpeak latency in Brainstem 
auditory evoked potentials.29 
 Another study on Brainstem evoked response audiometry done byMaria 
Carolina Braga NorteEsteves et al on sixty normal hearing subjects aged 9 and 66 
years showed statistically significant difference in wave latencies between males and 
females and no difference found between ears.31 
A study onage and gender effects on Auditory Brain Stem Response done by 
YonesLotfi et al on 120 subjects (60 males and 60 females) of three age groups: 18-
30, 31-50 and 51-70 years old, at a Rehabilitation Center in Tehran, Iran. Examined 
the age and sex influences on wave I and V absolute latency, and I-V IPL and showed 
that significantly shorter latency of wave I, V, and IPL I-V latency in females than 
males.The latency of wave I, V and IPL I-V in the 51-70 year old group was 
significantly higher than the 18-30 and 31-50 year old groups.33 
4.9.6. Clinical neurophysiological correlation: 9 
Although the changes in BAEPs are nonspecific, they provide information 
about the function of corresponding auditory pathways. So the abnormalities in BAEP 
should be correlated with the clinical picture and other investigations. 
4.9.7. Clinical applications of BAEPs: 9, 26, 31 
The most important clinical applications are to establish a minimal auditory 
response level, to assess the maturity of the central auditory system in neonates, to 
characterize the type of hearing loss, to assess the type and level of hearing loss in 
children below 5 years of age, to monitor surgery of the posterior fossa, to assess 
balance disorders, to define the site of auditory nerve or brainstem injury, to assess 
metabolic, demyelinating and  degenerative diseases and to monitor patients in 
intensive care units and as a prognostic predictor of coma and determination of brain 
death and to detect cerebellopontine angle tumors, intrinsic brainstem tumors,  
multiple sclerosis, to follow -up after operations concerning brainstem etc.31In the 
evaluation of suspected retrocochlear pathology ABR audiometry is used as an 
effective screening tool.9 
4.9.8. Abnormal BAEPs 11 
1) Absence of wave I : 
Causes: Large tumor damaging VIII nerve, VIII nerve ischaemia. 
2) Absence of wave beyond wave I : 
Causes: acoustic neuroma, meningioma, demyelinating disorders 
3) Absence of waves IV and V : 
Causes: multiple sclerosis, hydrocephalous 
4) Right to left latency asymmetry more than 0.5 msec is seen in acoustic 
neuroma 
4.9.9. Effect of ovarian hormones on auditory system: 37 
In addition to the regulation of reproductive behaviour, ovarian hormones 
regulate the activity of hypothalamic and extrahypothalamic noradrenergic, 
dopaminergic and serotonergic neurons. 
Role of Estrogen: 
Several studies have shown the effect of estrogen on the processing of hearing 
in humans, and this effect, in part, is thought to result from regulation of the 
transcription of genes via their classical estrogen receptor (ER) pathway. The actions 
of estrogen are mediated by estrogen receptors alpha and beta (ERα and ERβ), which 
act as transcription factors and are belongs to the nuclear receptor superfamily. 14In 
the inner ear of humans and animal models (rat and mice), estrogen receptors alpha 
(ERα) and beta (ERβ) have been identified mainly in spiral ganglion type I cells, the 
striavascularis and cochlear blood vessel.38 
 Estrogen receptors are also present in the outer and inner hair cells. This 
suggests that estrogen may influence auditory transmission. The receptors in the 
striavascularis may regulate the fluid and electrolyte balance in the cochlear fluids. 
The cochlear blood vessels contain receptors for estrogen, this may influence auditory 
function by modulating cochlear blood flow.37 
A study done by K. Charitidia et al in the Department of Physiology and 
Pharmacology, Sweden onthe expression of estrogen receptorsin the brain areas 
related to hearing in prepubertal and aged mice showed that the estrogen receptors are 
present throughout the central auditory system in different periods of maturation 
suggests that by regulating the transcription of genes via their classical estrogen 
receptor pathway, estrogen directly affect the processing of hearing in humans.14 
A study done by Thompson and colleagues demonstrated that 3 months 
treatment with tamoxifen showed auditory function changes in young adult female 
CBA mice. They also found that there is a decrease in suppression of distortion 
product otoacoustic emissions (DPOAEs) on blocking ER. This may be due to a 
reduction of the Medial Olivocochlear system (MOC) suppression. This decrease is 
same as that occurring in aging and before the onset of age related hearing loss and 
they suggest that in addition to its neuroprotective effect, estrogen was found to have a 
protective role on auditory function. One of the mechanisms involved in this 
protective effect may be the “genomic” action of estrogen on its membrane receptors- 
alpha and beta.37 
Role of Progesterone: 
Progesterone acts as a neurosteroid. Studies done in rat showed the presence of 
progesterone receptors within the inner ear such as the endolymphatic sac and 
striavascularis. By regulating endolymph and cochlear blood supply these structures 
play essential roles in underlying hearing mechanisms.39Progesterone may cross-react 
with other steroid receptors present in the cochlea or more proximal areas of the 
auditory system. GABA-A receptors are present throughout the auditory system. 
Progesterone and its metabolites act as GABA-A agonist and interact with the steroid 
binding sites on these receptors. By this way progesterone may affect the auditory 
system. It may affect auditory processing indirectly by decreasing the 5-HT levels.37 
 4.9.10. Auditory Evoked Potential in different phases of menstrual cycle:   
Conflicting studies are there regarding hormonal changes during menstrual 
cycle and the changes inAuditory Evoked Potential.Caruso et al., and Serra et al., 
reported shorter BAEP latencies during the periovulatory phase ofthe female sexual 
cycle and they suggest the reason for this as the high estrogen level in this 
phase.Stomati et al.,  showed that when the OVX rats are treated with estrogen there is 
a dose dependent increase in level ofallopregnaloneboth centrally and peripherally. 
According to Disney and CalfordGABA inhibition in the auditory pathway in the 
midbrain may get facilitated by an increase in neurosteroids (such as allopregnalone). 
In the luteal phase the ABR latency changes are due to the action of progesterone.37 
A Brainstem Auditory Evoked Potentials (BAEP) study conducted by 
Navapreet Mann et al.,Maulana Azad Medical College, New Delhi, on 50 young 
females of age group19-36 years, during four different menstrual cycle phases showed 
a significant increase in the waves, I to V peak latencies in the oestrogen peak mid 
cycle and a significant decrease in the same during progesterone peak mid-luteal 
phase. IPL did not show any statistically significant change in the above two phases. 
No significant changes occurred in the menstrual and the pre-menstrual phases. They 
suggests, BAEP changes in the mid follicular and the mid luteal phases of the 
menstrual cycle are attributable to the changes in oestrogen and progesterone during 
the cycle.7 
A study on Brainstem Auditory Evoked Potentials (BAEP) done by 
SandeepKaur et al., Adesh Institute of Medical Sciences & Research, Bathind, Punjab 
on 40 regular menstruating healthy females of age group 19 to 23years in three 
different menstrual cycle phases showed statistically significant increase in waves I, 
III and V absolute latencies in proliferative phase as compared to menstrual phase and 
a statistically significant decrease of the same parameters in secretory phase as 
compared to proliferative phase. They suggests that the central auditory conductivity 
is affected by the hormonal changes during menstrual cycle.40 
A Brainstem auditory evoked responses (BAERs)  study done by R Howard et 
al., University of Otago, Dunedin, New Zealand on 21 healthy control women and 30 
women diagnosed to have Late Luteal Phase Dysphoric Disorder (LLPDD) in three 
menstrual cycle phases showed no change in BAEP latencies in healthy control 
women at different menstrual cycle phases, increased wave III BAEP latency in 
females with moderate PMS symptoms compared to healthy controls and an increased 
waves III and V BAEP latencies in women with severe PMS symptoms compared to 
healthy controls.41 
A Brainstem auditory evoked responses (BAERs) study done in three different 
menstrual cycle by Salvatore Caruso et al on 94 women after the third month of oral 
contraceptive intake showed decrease in wave latencies and inter-peak intervals 
during the periovular phase as compared to the luteal phase. They suggested BAEP 
seems to be depend on the hormonal variations that occur in each menstrual cycle and 
also during oral contraceptive intake.42 
Auditory Evoked Potential study done by A. Zani from the Instituto di 
Psicologia del C.N.R., Rome, Italy on eight young female athletes of age group 20 to 
24 years who were undergoing regularly and intensively training in different sports , 
of which four are on oral contraceptives and four without oral contraceptives showed 
a constantly increasing delay in wave V latency on moving from menstrual phase to 
midcycle (ovulatory phase) and sharp decrease in the same in premenstrual days.They 
suggested this may be due to the neurofunctional interactions between different level 
neural structures and gonadal steroid hormones.32 
A study on auditory brainstem response (ABR) was done by 
NamrataUpadhayay et al., on 40 healthy female volunteers of age group19 ± 2.35 
years. The ABR latency of wave V, IPL III–V and I–V were shorter in postovulatory 
phase as compared to the preovulatory phase. They concluded that compared to 
preovulatory phase ABR is better in postovulatory phase, this may be due to the effect 
of progesterone in this phase.43 
A Long latency auditory evoked potential study was done by AshaYadav et al., 
University College of Medical Sciences & GTB Hospital, Delhi on 20 females having 
normal ovulatory menstrual cycles and twenty control females of same age group 
having anovulatory menstrual cycles on oral contraceptive (O.C.) pills, across the four 
different menstrual cycle phases. They proved that the central processing of the 
auditory informationis modified by the variations in estrogen and progesterone in a 
normal cyclic female .44 
A study on auditory brainstem responses (ABR), mid-latency responses 
(MLRs) and slow vertex responses (SVRs), done by AshaYadav et al., 
University College of Medical Sciences & GTB Hospital, Delhi on 20 women in four 
different menstrual cycle phases showed that in estrogen-peak mid-cycle there is an 
increase in peak latencies of ABR waves III and V and IPL I-V, and in progesterone-
peak midluteal phase there is a decrease in latencies. Peak latencies of MLR waves 
also show a same trend. In the mid-cycle there was a significant decrease in SVR 
waves P2 and N2 while conduction is faster in midluteal phase.All the waves showed 
shortest latencies during menstruation. They suggest that during the menstrual 
cyclethe ovarian steroids are modulating the whole auditory neural conduction and the 
effects are better visible on the central component.45 
 
 
4.10. Visual Evoked Potential (VEP) 
In 1930s the changes evoked by visual stimuli were recorded directly from the 
surface of the pia mater in animals for the 1st time.28 
Visual Evoked potential (VEP) is one of the electrophysiological technique 
which is used by neurophysiologist, ophthalmologist, and neurosurgeons for better 
diagnosis of optic nerve fibre and visual cortex diseases such as Multiple Sclerosis, 
Optical neuritis etc.46The electrical potential differences recorded from scalp in 
response to visual stimuli is known as Visual Evoked Potential (VEP). It represents a 
resultant response of cortical as well as subcortical areas to photostimulation. It assess 
the optic nerve conduction up to the visual cortex "area 17". VEPs are one of the most 
useful tool in testing optic nerve function.25VEPs depend on functional integrity of 
central vision at any level of the visual pathway including the eye, retina, the optic 
nerve, optic radiations, and occipital cortex.47 Many neurological disorders present 
with visual abnormalities and detection of subclinical lesions affecting the visual 
system which are poorly visualized by MRI or in unreliable clinical examination or 
ruling out of psychogenic origin, depends mainly on the VEPs.28 
The Visual Evoked Potentials or the Visual Evoked Responses are the evoked 
potentials produced when the retina is stimulated with light (flashes/pattern 
stimulation) and the potentials are generated in the cortical and sub-cortical visual 
areas and best recorded over the occipital region. It is a very important non-invasive 
tool in detecting visual system abnormalities.28 
4.10.1. Anatomical basis of Visual Evoked Potential: 
 On exposure to light, the photoreceptors, rods and cones get stimulated. These 
receptors synapse with bipolar cells then with the ganglion cells. The axons of 
ganglion cells form the optic nerve. The optic nerve is about 5 cm long and it extends 
from the retina to the optic chiasma. About 1million optic nerve fibres are 
unmyelinated in the retina and in the optic nerve head, but get myelination as these 
pass through the optic chiasma located above the sellaturcica. The optic nerve fibres 
primarily carry visual impulses and also impulses for accommodation and reflex 
response to light and other stimuli. The fibres from temporal half of the retina are 
located in the temporal half of the nerve and it pass through the chiasm without 
crossing to the opposite side and continue to the ipsilateral reflex centres for pupillary 
reaction and ipsilateral visual areas. The optic nerve fibres from the nasal half of 
retina pass through the medial portion of nerve, cross at the chiasm and terminate at 
the contralateral cortex. In the optic chiasm, the fibres from upper retinal quadrant 
occupy dorsal and those from the lower retinal quadrant occupy ventral areas. The 
fibres associated with central vision coming from macula form papillomacular bundle 
in the peripheral portion of optic nerve. As the nerve approaches the chiasma the 
papillomacular bundle approaches the centre of the nerve and the temporal fibres are 
lateral. The fibres from the medial half of the macula decussate, but not the lateral. 
From optic chiasma optic tract starts and end in lateral geniculate body. The optic tract 
consists of ipsilateral temporal and contralateral nasal retinal fibres. From the optic 
tract fibres responsible for pupillary reflex pass to EdingerWestphal nucleus. The 
fibres carrying impulses from upper portion of retina terminate in ventromedial 
segment and the lower portion in ventrolateral segment of lateral geniculate body. The 
macular fibres occupy an intermediate position in the dorsal, middle and caudal 
portion of lateral geniculate body. In the lateral geniculate body, the ipsilateral 
temporal and contralateral nasal retinal fibres alternatively terminate in six layers. 
From here the neurons form optic radiation terminate in striate cortex (area 17).The 
macular fibres end in the occipital lobe at the pole in a wedge-shaped area. The upper 
half of retinal fibres relay superior and the lower half inferior to the calcarine fissure. 
 The P100 waveform of VEP is generated in the striate and peristriate occipital 
cortex. It occurs due to activation of primary cortex and thalamocortical volleys. On 
giving pattern or flash stimulation the metabolism in primary visual area and visual 
association areas (area18 and 19) increases. The regional cerebral blood flow 
increases with stimulation rate up to 8 Hz and gradually declines thereafter. Recently, 
the origin of first major component of VEP on pattern shift stimulation has been 
reported to originate from primary visual cortex. 
 The retinal ganglion cells are classified into X and Y cells. The X cells are 
small retinal ganglion cells with small diameter axons. They mediate cone vision with 
lateral inhibition. They have a small receptive field and distributed in the central part 
of retina. They have low sensitivity to motion and provide substrate for pattern shift 
VEP (PSVEP) via geniculate pathway. Thus they are useful in assessing the visual 
acuity. 
 The Ycells are large retinal ganglion cells with large diameter axons. They 
mediate rod vision without lateral inhibition. They have a large receptive field and 
distributed in the peripheral part of retina. They have high sensitivity to motion and 
provide substrate for flash VEP via extra geniculate pathway. Thus they determine the 
presence or absence of light perception. 
 VEP primarily reflect the activity originating in the central 3º to 6º of visual 
field which is relayed to the surface of occipital lobe. The projections arising from the 
peripheral retina are directed to the regions deep within the calcarine fissure, hence 
unrecordable on peripheral retinal stimulation.9 
4.10.2. Types of VEPs: 
1. Transient VEP: Stimulus given at a relatively low rate (up to 4/s) 1Hz produce the 
reversal pattern every 500 msec.11, 48 
2. Steady state VEP: Stimulus is given at higher rates (10/s or higher) 4-8Hz.The 
steady state VEP are repeated evoked potentials which constitute discrete frequency 
components and remain constant in amplitude and phase over long period of time.  
3. Pattern VEP: This was developed and popularized in the early1960s.28 Responses 
elicited by patterned stimuli are called “pattern” VEPs or PVEPs.  
Compared to unpatterned stimuli, patterned visual stimuli evoke responses 
show less intra- and inter individual variability. With this even minor visual pathway 
abnormalities can be detected with much greater sensitivity and accuracy as compared 
to Flash VEP testing.48 
The most frequently and widely used pattern stimulus to assess visual pathway 
defects in clinical investigations is checkerboard pattern reversal because they elicit 
relatively large potentialsand it is more sensitive to the visual pathway conduction 
abnormalities. It is estimated that 65% of the pattern-reversal response is generated in 
fovea.25The checks alternate from black to white and vice versa at every 1 or 2 
seconds. Each alternation acts as stimulation and produces an evoked potential at the 
occipital lobe.49It is an useful clinical tool in the diagnosis and documentation of 
visual impairment in pediatric and adult neurologic disorders. 
4.10.3. Characteristics of pattern reversal stimulation 25 
In 1980 Erwin outlined 7 basic characteristics of pattern-reversal stimulation: 
1. Rate of pattern-reversal: It is the number of times that the pattern changes 
within a second. Usually all the pattern reversal responses are averaged 
together. 
2. Reversal time: It is the total time taken to change from one pattern to its 
opposite. 
3. Stimulus luminance is an important attribute for visual stimulus. 
4. Type of the pattern used is very important. Checkerboard stimulus is most 
commonly used. 
5. Orientation of the pattern: Vertical-horizontal orientation elicit larger responses 
as compared to oblique orientation.  
6. Size of the pattern elements: It can be described in two ways. The visual angle 
subtended by each element can be measured. Also, the spatial frequency can be 
used.  
7. Another aspect is the spatial rate of luminance change.  Field size and 
relationship to fixation are the most important aspects of the stimulus .25 
 
4.10.4. Normal Pattern Shift Visual Evoked Potential (PSVEP): 
A high contrast black-and-white checkerboard spanning the central 20˚–30˚ of 
the visual field is used as the visual stimulus. The black and white squares periodically 
exchange places. The averaged response to this reversal is considered as VEP.26 
In normal subjects, the pattern reversal evoked potential to full field stimulation 
consists of three peaks.25 Two negative waveform denoted as N and the positive 
waveform as P, which is followed by the approximate latency in milliseconds. The 
commonly used waveforms are N70, P100 and N135. The subscript number denotes the 
time in milliseconds after stimulation.11 
A prominent positive wave (called P100), appears almost 100 ms after the 
pattern reversal, this signal is picked up by the midline occipital electrode normally. 
The waveforms at the lateral electrodes are variable and the midline electrode shows 
the latency of P100 so it is taken as the measure of retino-striate conduction time.26 
 The measurement of P100 peak latency, its duration and amplitude for VEP 
analysis is most commonly used. P100 latency is least affected by technical factors 
and degree of patient cooperation and its prolongation is the most reliable indicator of 
clinically significant abnormality.48 
4.10.5. VEP waves and their site of origin:  
P100 waveform generated in the striate and pre-striate occipital cortex, due to 
activation of primary visual cortex and thalamocorticalfibers discharge.25 
The VEP is primarily a reflection of activity originating in the central 3º to 6º 
of the visual field as the retinal projections from this area is relayed to the surface of 
the occipital lobe while those from the peripheral areas are directed to deeper regions 
within the calcarine fissure. Therefore, when scalp electrode picks up the signals 
directly from the cortical tissue that receives the central inputs. VEP is mainly a 
reflection of the cone activity.9 
On giving visual stimuli, there is increased metabolism in the primary visual 
area and also in the visual association areas 18 and 19.The cerebral blood flow is 
found to increase with increase in stimulation rate up to 8 Hz but declines gradually 
thereafter. Using intracerebral recording in awake humans, it is found that P100 
appears to be generated by the pyramidal cells in layer IV of area 17. According to the 
imaging studies the source of the early phase of the P100 peak appears to be in dorsal 
extrastriate cortex of the middle occipital gyrus, whereas the late phase of P100 
generated by the ventral extrastriate cortex of the fusiform gyrus. These results 
suggest the cortical generation of VEP waveforms.28 
 N70 waveform – reflects the activity in the fovea and primary visual cortex.11 
 N135 waveform – reflects the activity in the visual association area 18 and 19.11 
 Figure 4: Visual Evoked Potential Waveform 
Table 2: Normal values ofVEP: 9 
Parameters (Mean ± SD) 
P 100 Latency (ms) 96.9 ±3.6 
R-L (ms) 1.5±0.5 
Amplitude (µV) 7.8 ±1.9 
Duration 55.9 ± 7.7 
 
 
4.10.6. Factors affecting VEP (P100 waveform)  
a. Technical factors 25 
1. Screen luminance: P100 latency increase with decrease in brightness. The 
pupillary diameter also affect P100 latency , as this has an effect on retinal 
illumination. Decrease in area of retinal illumination reduces the amplitude and 
increase the latency of VEP. 
2. Degree of contrast: On reducingthe degree of contrast between the black and white 
squares of checkerboardpattern P100 latency increases and amplitude reduces. 
3. Size of the stimulating pattern: When the size of the stimulating pattern (degree 
of visual angle) decreases the amplitude of the response decreases . 
4. Check size: Smaller checks will produce highest amplitude responses. 
5. Electrode placement: More anterior placement of electrodes results in shorter VEP 
values. 
6. Stimulus rate 
When the stimulus rate is increased beyond 8 per second, the evoked responses 
will change to steady state evoked potential. 
b. Physiological factors 25, 50, 51, 52  
1. Age: In young children and infants, the P100 latency on large checks reaches the 
adult value by 20 weeks and the latency on smaller checks takes 5-6 years to reach the 
adult value. This is due to the age related changes in retina and the rostral part of 
visual system. The mean amplitude is almost double of adult value in the first decade 
of life 
2. Sex: Latency is larger in males compared to females. This may be due to large head 
size and low core temperature of the body in males. The mean amplitude is higher in 
females compared to males, probably due to hormonal differences. 
3. Eye dominance: Shorter latency and higher amplitude of P100 wave obtained on 
stimulating the dominant eye compared to the non dominant eye. 
4. Hemispherical dominance: The amplitude of P100 wave is greater in right 
hemifield stimulation in right handed individuals due to neuroanatomic asymmetries 
of human striate cortex. 
5. Occular movement: The amplitude of P100 wave is reduced by eye movement. 
6. Visual acuity: The latency and amplitude remains normal with visual acuity as low 
as 20/120, however the amplitude decreases with further decrease of visual acuity. 
7. Mental activity: Decrease latency and increase amplitude of P100 waveform. 
8. Drugs: P100 latency increases with use of miotics and decreases with mydriatics. 
Carbamazepines prolong VEPs. 
9. Serum glucose level: P100 latency increased with increasing serum glucose level, 
with a 6.9% estimated latency difference between lower and higher glucose 
concentrations.25 
A study done by Anju Thakur Jha, ParveenSiddiquiYousuf  andSwarnaBiseria 
Gupta, LN Medical College & Research Center, Bhopal, to find the effect of myopia 
on visual evoked potential on 130 healthy volunteers of age between 17-21yrs of both 
sex, grouped as without refractive error N=69 (F=36 & M=33) and with refractive 
error N=61 (F=31 & M=30) showed statistically highly significant difference in 
latency of P100 between both eyes in group with refractive error and N75-P100 
amplitude difference also shown high statistical significance in the group with 
refractive error.51. 
 A study done by Ruchi Kothari et al in Department of Physiology, MGIMS, 
Sevagram, Wardha, Maharashtra to find the effect of refractive errors on visual 
evoked potentials showed that prolonged P100 latency and reduced amplitude with 
refractive errors. They concluded that the VEPs seem to be more affected by myopia 
than hypermetropia.52 
4.10. 7.VEP abnormalities: 11 
1. Prolongation of latency: Commonest cause is demyelination in optic pathways. This 
results in delayed conduction in the visual pathway. 
Causes: multiple sclerosis, optic neuritis (alcoholism, vitamin B12 deficiency, 
tobacco), glaucoma. 
2. Reduction in amplitude: Axonal loss due to ischaemic optic neuropathy produces 
reduction in amplitude of P100 waveform. 
Causes: Hypertension, CNS vasculitis refractory errors, media opacities, and retinal 
diseases. 
3. Both amplitude and latency abnormalities: Optic nerve compression produces 
segmental demyelination and axonal loss resulting in increase in latency and reduction 
in amplitude. 
Causes: Severe papilloedema, pituitary tumour.11 
4. Shape abnormalities: Bifid pattern of P 100 , that is two peaks separated by 10-50 
msec, get in visual field defects. This may be due to shifting of transitional zone. 
4.10.8. Physio-clinical significance of VEP: 
In uncooperative subjects where fundus examination is not possible VEP 
testing is necessary.VEP provide an objective and sensitive information of 
abnormalities in visual system especially anterior to optic chiasma.9 
4.10.9. Clinical usefulness of VEPs:  
The major use of VEPs is in the detection of sub-clinical lesions within the 
visual system; asymptomatic optic neuritis is easily detected and its presence may aid 
in the diagnosis of MS.  VEPs an important adjunct when the diagnosis of 
demyelinating disease is in doubt, as the optic nerve abnormalities are poorly 
visualized by MRI. A normal VEP excludes significant optic nerve or anterior 
chiasmatic lesion thus it helps to assess patients with subjective complaint of visual 
loss. It will also help to distinguish blindness from hysteria and malingering: if a 
patient reports visual loss, a normal VEP strongly favors a psychogenic disorder.28 
In infants, VEPs has been used to assess integrity of the visual system when 
blindness is suspected and also to detect unilateral amblyopia at an early age when 
recovery may still be possible.28 
 VEP is useful in the diagnosis ofMultiple sclerosis, Optic Neuritis, Ischemic 
Optic Neuropathy, AIDS-related ocular lesions, Toxic amblyopia, Glaucoma, 
Retrobulbar neuritis, Tumors compressing the optic nerve, Vitamin B12 and E 
deficiency,  Malingering and hysteria, Intra-operative monitoring in pituitary and 
cavernous sinus tumor. 25, 26 
4.10.10. Effect of ovarian hormones on Vision: 
In young females, the retina and retinal pigment epithelium (RPE) of eyes 
showed 65-kDa ERα protein. ERα is also detected in the ciliary body, iris, and in the 
epithelium of the lens.23Various studies reported that estrogen increase the sensitivity 
of receptors in the optic pathways to dopamine and thereby decreases the visual 
transmission time. 50 
4.10.11. VEP studies in menstrual cycle: 
A study done by Luiz Antonio De Lima Resende et al, in Department of 
Neurology and Psychiatry, State University of São Paulo (UNESP) on pattern-shift 
visual evoked potentials (PS-VEP) in 20 female volunteers of ages 23 to 26 years at 
different menstrual cycle phases showed decreased latencies for P100 (PS-VEP) wave 
in the progesterone phase..13  
A study done by Yasuhiro Kaneda et al in the Department of Neuropsychiatry, 
Japan on visual evoked potential (VEP) and electroencephalogram (EEG) changes in 
the menstrual cycle in regularly menstruating healthy females, with 21 at the follicular 
phase (FP) and 23 at the luteal phase (LP) showed that the VEP and late EEG changes 
at LP reflect the effect of progesterone more than estrogen.53  
A study done by ParveenSiddiquiYousuf and Anju Thakur Jha in  LN Medical 
College & Research Center, Bhopal, to find the effect of phases of menstrual cycle on 
visual evoked potential on 40 healthy female volunteers of age between 17-21yrs with 
regular menstrual cycle tested on follicular and luteal phaseshowed that prolongation 
of P100 latency during luteal phase.50 
A Visual Evoked Potential study done byMohsen Azarmina, MasoudSoheilian, 
HosseinAzarmina, and ShahidBeheshti, University of Medical Sciences, Iran, on15 
females of  age 18 to 25 years in the follicular phase and luteal phase showed 
prolonged VEP latency in the luteal phase .54 
A Pattern reversal Visual Evoked Potential study done by Sangeeta Gupta et 
alon20 women of age group18-25 years, in the menstrual cycle phases (proliferative 
and luteal phases) showed statistically significant reduction in mean P100 PRVEP 
latency in the proliferative phase as compared to the luteal phase and a statistically 
insignificant increase in N75-P100 amplitude in the luteal phase.55 
 
 
  
 
 
 
 
 
 
 
 
5. MATERIALS AND METHODS  
5.1. Study design: 
 This study was designated as cross sectional study. 
5.2. Study setting;  
 The study was conducted in Department of Physiology, SreeMookambika 
Institute of Medical Sciences, Kulasekharam (Kanyakumari District), Tamilnadu. 
5.3. Study period: 
 This study was done during the time period from January 2014 to April 2015 
for over a period of 16 months. 
5.4. Sampling technique: Non randomized purposive sampling method. 
5.5. Scientific basis of sample size used in this study: 
The sample size of this study was determined based on the studies published in 
literature.  
The formula used is n= (u+v)2×(SD12+SD22)/(µ1-µ2)2 
           u=0.84 for 5% level of significance. 
           v=1.96 for 80% power. 
 According to previous study done by Mann et al7 the Standard deviation 
1(SD1) is 0.22, Standard deviation 2 (SD2) is 0.23,Mean 1 (µ1) is 5.62 and mean 2 
(µ2) is 5.52. 
           SD1=0.22 
           SD2=0.23 
           µ1=5.62 
           µ2=5.52 
Hence by applying the formula,  
 n = (0.84+1.96)2× (0.22)2+ (0.23)2 /(5.62-5.52)2 
= 7.84×(0.0484+0.0529)/(0.1)2 
  = 7.84×0.1013/(0.1)2 
 = 7.84×0.1013/0.01 
 = 0.794192/0.01 
 = 79.4192 
5.6. Study group: 
 This study was conducted in 80healthy female nursing students of age18-20 years 
with regular menstrual cycle and normal Body Mass Index.  
  
5.7 Inclusion criteria: 
1. All first year Female Nursing Students of SMIMS with  regular menstrual cycle 
(lasting 28 – 32 days.)  
2. Age group: 18-20 years. 
3. Body mass index: 18-25kg/m 2 
4. Femaleswith normal visual acuity. 
5.8. Exclusion criteria: 
1. History of irregular periods. 
2. History of drug intake (eg: hormonal pills, steroids, anti-depressants, 
neuroactive substances etc)  
3. History of dysendocrinism, metabolic or neoplastic pathologies. 
4. History of chronic illness, neurologic or psychiatric illness. 
5. Auditory defects (eg: conductive hearing loss, sensorineural hearing loss). 
6. Visual defects (eg:colour blindness). 
7. Pregnancy, lactation. 
5.9. Parameters to be studied 
BRAIN STEM AUDITORY EVOKED POTENTIAL (BAEP) 
Peak latencies   (Milli Second), of the waves I,II,III,IV and V , inter peak latencies 
of  I- V, I-III and III- V, and the amplitude ratio(V/I ). 
VISUAL EVOKED POTENTIAL (VEP)  
P100 peak latency (Milli Second) and amplitude (micro volt) 
5.10. Methods /Instrument:  
The instrument used for the study was computerized RMS ALERON 401 
EMG/NCV/EP measuring system designed for any neurophysiological application. 
The instrument was supplied by records and Medicare systems Pvt. Ltd. Chandigarh, 
India. 
5.11. Institutional Human Ethical Committee (IHEC) Approval : 
Before conducting the study, the study proposal was submitted to the 
Institutional Human Ethical Committee (IHEC) of SreeMookambika Institute of 
Medical Sciences (SMIMS) Kulasekharam, K.K District, Tamilnadu, for approval and 
same was approved by the Institutional Human Ethical Committee SMIMS with Ref. 
No. SMIMS/IHEC/2013/C/06.The certificate of approval has been enclosed in 
annexure. 
5.12. Procedure in brief: 
After getting the approval from Institutional research committee (IRC) and 
Human Ethical Committee (HEC),written informed consent was obtained from all the 
volunteers before enrolling them into the study. 
The study was conducted in the department of physiology. 80 female first year 
nursing students of age 18-20 years with regular menstrual cycle (lasting 28-32 days) 
was selected. The subjects with normal body mass index (18 -25kg/m2) and those who 
were not taking any hormonal pills during the past 6 months were included in this 
study. A detailed menstrual history was taken from each subject. Before conducting 
the BAEP and VEP, a priliminary selection tests on hearing, vision and 
anthropometric data was taken. Tuning fork tests like Rinne’s and Weber’s test and 
otoscopy was performed to exclude any conduction defect. Snellen’s chart, Jaeger’s 
chart and Ishihara’s chart testing was done to exclude decreased visual acuity and 
colour blindness. 
During their menstrual cycle each women was subjected to three brain stem 
auditory evoked potential (BAEP) and visual evoked potential (VEP) testings, the first 
at the menstrual phase (day 1-4),the second at the proliferative phase (day 5-14), the 
third at the secretory phase (day 15-28).56 The day of ovulation was found out by the  
basal body temperature chart and a retrospective calculation was done from the day of 
onset of the next menstrual cycle. Before conducting the BAEP and VEP tests, each 
subject was seated comfortably in an arm chair in an electrically and acoustically 
shielded room with dimmed light. The subjects were briefed about the procedure and 
asked for their co-operation throughout the procedure. To avoid the postprandial drip 
in sensory perception and performance and diurnal variation, the tests were conducted 
between 10 and 12 am. 
  
Pre-test instructions: 
 The subjects were asked to shampoo wash their hair on the previous day of the 
test and to avoid hair chemicals, oils and lotions. 
 Advised to avoid intake of drugs or foods containing caffeine on the day and 
the previous day of the test. 
 Advised to take adequate sleep on previous night. 
 Subjects were restricted from use of sedatives, miotic or mydriatric drugs on 
the day and the previous day of test. 
 They are asked to wear the spectacles or contact lenses during the test if using, 
to prevent refractive errors. 
Brainstem Auditory Evoked Potential (BAEP) Maneuver: 11 
 By using electrode paste the recording (active) electrodes were pasted on the 
mastoid process of both ears, reference electrode at vertex Cz and the ground 
electrode in front of the vertex that is at the Fz according to the 10–20 international 
system of EEG electrode placement. The site of application was cleaned with an 
abrasive cleanser (spirit) before the electrode placement. All electrodes were plugged 
to a junction box and skin to electrode impedance was kept below 5 Kohm.  2000 
click stimuli which had an intensity of 70dB above the normal hearing threshold were 
given to each ear seperately, at the rate of 11.1/sec and for a duration of 0.1 ms. The 
stimulation was of the rare-type, with a linear envelope. The sweep speed was 
1ms/division and the sensitivity was 0.5μV/div. These clicks were generated by 
passing 0.1 ms square pulses through shielded headphones. Contralateral 
(nonstimulated) ear was masked by white noise at 40 dB SPL to eliminate “crossover” 
responses, i.e., bone-conducted responses originating in this ear. The low cut filter 
was set at 100 Hz and high cut at 3 kHz.Signals picked up by electrodes were filtered, 
amplified, averaged and displayed on the screen ofBERA machineand hard copy of 
the recordings were taken. A series of five waveswere recorded during the first 10 ms 
after giving the auditoryclick stimulus. The peak latencies of the waves, I, II, III, IV 
and V, the inter peak latencies of I-V, I-III and III-V, and the amplitude ratio (V/I) 
were recorded. Both the ears of each woman were treated as separate samples and 
thus, the ABR wave forms were analyzed separately for each ear. 
Visual Evoked Potential (VEP) Maneuver: 11 
The subjects were seated comfortably 100 cm away and in front of the monitor. 
By using electrode paste the active  electrode was pasted  on the occiput (Oz), 
reference electrode was kept at about 12 cm above the nasion  (Fpz) and the ground 
electrode over the vertex (Cz) according to the 10–20 international system of EEG 
electrode placement. The site of application was cleaned with spirit before the 
electrode placement. All electrodes were plugged to a junction box and skin to 
electrode impedance was kept below 5 Kohm. The visual stimuli were alternate black 
and white checkerboard patterns (contrast 70%, mean luminance 50 cd/m2) generated 
on a video monitor. The check edges subtend a visual angle of 15 minutes with video 
monitor screen subtending an angle of 12.5°. The subjects were asked to fixate their 
one eye (other being closed with a patch) on the central spot of the TV monitor. Each 
eye was tested separately (monocular testing). The reversal rate of checks is kept as 
twice per second. Every time the pattern alternates, the subject's visual system 
generates an electrical response that was detected and recorded by surface electrodes. 
300 stimuli was given at the rate of 1.71/sec and for a duration of 500ms. The sweep 
speed was 30ms/division and the sensitivity was 5μV/div. The low cut filter was set at 
2 Hz and high cut at 100 Hz.Signals picked up by electrodes were filtered, amplified, 
averaged and displayed on the screen ofVEP machineand hard copy of the recordings 
were taken. P100 peak latency and amplitude was recorded. Both the eyes of each 
female were treated as separate samples and thus, the VEP wave forms were analyzed 
separately for each eye. 
After completing the BAEP and VEP recordings in all the three menstrual 
cycle phases, the hard copies of the same were maintained in separate files and the 
results obtained were analysed with standard normal values. 
5.13. Statistical methods of analysis: 
1. P value <0.05 was considered as statistically significant. 
2. The statistical analysis was done by using one way ANOVA Posthoc test 
followed by Dunnet t test with the statistical parameters like mean and standard 
deviation.  
3. Data was entered in Microsoft excel 2007 office and was analyzed using 
statistical software SPSS – 16.0.version. 
 
 
 
 
  
 
 
 
 
 
 
6. RESULTS 
6.1. Study subjects: 
In the present study, total 80 subjects were recruited after considering inclusion 
and exclusion criteria. They were tested in three different menstrual cycle phases. The 
baseline characteristics of the study subjects have been depicted in the table 3and 4. 
Table-3: Distribution of subjects based on the Age data 
Age (Years) Number Percentage (%) 
18 years 61 76.25 
19 years  19 23.75 
(MEAN±SD) 18.23±0.43 100 
 
Table-4: Distribution of subjects based on the BMI data 
Body Mass Index  Number Percentage (%) 
18-20 52 65.00 
21-23 20 25.00 
Above 23 8 10.00 
(MEAN±SD) 20.38±1.61 100 
 
6.2.Assessment of latency changes in Brainstem Auditory evoked potential 
(BAEP): 
The study showed statistical significant decrease in latency of BAEP wave V 
on the right side (p <0.05) and also in the left side (p <0.05) during proliferative phase 
(phase 2) of menstrual cycle as compared to secretory phase (phase 3) and an increase 
in latency of the same wave during secretory phase (phase 3) as compared to 
menstrual phase (phase 1). The latencies of waves I, II,III and IV showed the same 
trend but statistically insignificant. There is no significant difference in the latency 
changes of BAEP on the right side when compared to the left side (p>0.05). The 
latency changes during different phases has been depicted in the table 5, 6 and 7. 
Data are represented as Mean ± SD 
BAEP: Brainstem Auditory Evoked Potential 
 Number of subjects: 80 in each phase  
Phase -1: Menstrual phase  
Phase -2: Proliferative phase 
Phase -3: Secretory phase 
p< 0.05 is significant  
Data are analyzed by one way  ANOVAPosthoc test followed by Dunnet t test.   
Table-5: Comparison of mean BAEP wave latencies (ms) of right ear in different 
menstrual cycle phases 
BAEP waves 
Latencies (ms) 
Phase-1 
(Mean±SD) 
Phase-2 
(Mean±SD) 
Phase-3 
(Mean±SD) 
Wave-I 1.67±0.05 1.66±0.12 1.68±0.13 
Wave-II 2.78±0.12 2.78±0.07 2.79±0.13 
Wave-III 3.65±0.09 3.64±0.14 3.66±0.09 
Wave-IV 5.00±0.17 4.99±0.34 5.11±0.38 
Wave-V 5.73±0.36 5.51±0.31 5.92±0.52* 
(*P<0.05 significant compared Phase-2 with Phase-3 at wave-V) 
Table-6: Comparison of mean BAEP wave latencies (ms) of left ear in different 
menstrual cycle phases 
BAEP waves 
Latencies (ms) 
Phase-1 
(Mean±SD) 
Phase-2 
(Mean±SD) 
Phase-3 
(Mean±SD) 
Wave-I 1.68±0.04 1.66±0.11 1.68±0.08 
Wave-II 2.79±0.11 2.77±0.07 2.79±0.13 
Wave-III 3.65±0.09 3.64±0.13 3.66±0.09 
Wave-IV 5.00±0.16 4.99±0.34 5.11±0.38 
Wave-V 5.72±0.36 5.52±0.32 5.91±0.43* 
(*P<0.05 significant compared Phase-2 with Phase-3 at wave-V) 
  
Fig.5: Comparison of mean BAEP wave latencies (ms) of right ear in different 
phases of menstrual cycle 
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Fig. 6: Comparison of mean BAEP wave latencies (ms) of left ear in different 
phases of menstrual cycle 
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Table-7: Comparison of mean BAEP wave latencies (ms) of left and right ear in 
different menstrual cycle phases 
BAEP waves 
Phase-1 
Wave-I Wave-II Wave-III Wave-IV Wave-V 
Right ear 1.67±0.05 2.78±0.12 3.65±0.09 5.00±0.17 5.73±0.36 
Left ear 1.68±0.04 2.79±0.11 3.65±0.09 5.00±0.16 5.72±0.36 
BAEP waves 
Phase-2 
Wave-I Wave-II Wave-III Wave-IV Wave-V 
Right ear 1.66±0.12 2.78±0.07 3.64±0.14 4.99±0.34 5.51±0.31 
Left ear 1.66±0.11 2.77±0.07 3.64±0.13 4.99±0.34 5.52±0.32 
BAEP waves 
Phase-3 
Wave-I Wave-II Wave-III Wave-IV Wave-V 
Right ear 1.68±0.13 2.79±0.13 3.66±0.09 5.11±0.38 5.92±0.52 
Left ear 1.68±0.08 2.79±0.13 3.66±0.09 5.70±0.38 5.91±0.43 
(P>0.05 no significant difference compared right and left ear waves in different 
phases) 
 
6.3. Assessment of Inter-peak latency changes in BAEP: 
The study showed statistical significant decrease in inter-peak latencies III-V 
and I-V of Auditory evoked potential on the right side (p <0.05) and also in the left 
side (p <0.05) during proliferative phase (phase 2) as compared to secretory phase 
(phase 3) and a statistical significant increase of the same inter-peak latencies during 
secretory phase (phase 3) as compared to menstrual phase (phase 1) .The inter -peak 
latency I-III showed the same trend but statistically insignificant. There is no 
significant difference in the inter-peak latency changes of BAEP on the right side 
when compared to the left side (p >0.05). The inter-peak latency changes during 
different phases have been depicted in the table 8, 9 and 10. 
Table-8: Comparison of mean inter peak latencies (ms) of right ear in different 
phases of menstrual cycle 
Inter peak latencies (ms) 
Phase-1 
(Mean±SD) 
Phase-2 
(Mean±SD) 
Phase-3 
(Mean±SD) 
Wave latency (I-III) 1.99±0.25 1.98±0.23 2.01±0.35 
Wave latency (III-V) 2.08±0.26 2.01±0.35 2.13±0.31* 
Wave latency (I-V) 4.04±0.30 3.99±0.46 4.14±0.33* 
(*P<0.05 significant compared Phase-2with Phase-3 at inter peak-latencies (III-V) 
and (I-V)) 
 
Table-9: Comparison of mean inter peak latencies (ms) of left ear in different 
phases of menstrual cycle 
Inter peak latencies 
(ms) 
Phase-1 
(Mean±SD) 
Phase-2 
(Mean±SD) 
Phase-3 
(Mean±SD) 
Wave latency (I-III) 1.99±0.25 1.99±0.23 2.00±0.34 
Wave latency (III-V) 2.09±0.26 2.02±0.35 2.14±0.30* 
Wave latency (I-V) 4.04±0.30 3.98±0.46 4.15±0.33* 
(*P<0.05 significant compared Phase-2 with Phase-3 at inter peak latencies at 
(III-V) and (I-V). 
 
 
 
 
 
 
 
Table-10: Comparison of mean inter peak latencies (ms) between right and left 
ear in different phases of menstrual cycle 
Inter peak latencies 
(ms) Phase-1 
I-III 
(Mean±SD) 
III-V  
(Mean±SD) 
I-V  
(Mean±SD) 
Right ear 1.99±0.25 2.08±0.26 4.04±0.30 
Left ear 1.99±0.25 2.09±0.26 4.04±0.30 
Inter peak latencies 
(ms) Phase-2 
I-III 
(Mean±SD) 
III-V  
(Mean±SD) 
I-V  
(Mean±SD) 
Right ear 1.98±0.23 2.01±0.35 3.99±0.46 
Left ear 1.99±0.23 2.02±0.35 3.98±0.46 
Inter peak latencies 
(ms) Phase-3 
I-III 
(Mean±SD) 
III-V  
(Mean±SD) 
I-V  
(Mean±SD) 
Right ear 2.01±0.35 2.13±0.31 4.14±0.33 
Left ear 2.00±0.34 2.14±0.30 4.15±0.33 
(P>0.05 no significant difference compared between right and left ear inter peak 
latencies at different phases) 
 
 
 
6.4. Assessment of amplitude ratio changes in BAEP: 
 The study showed statistical insignificant decrease in amplitude ratio of  BAEP 
on the right side (p >0.05) and also in the left side  (p >0.05) during secretary phase 
(phase 3) as compared to proliferative phase   (phase 2). Also showed a statistically 
insignificant increase in the same during proliferative phase (phase 2) as compared to 
menstrual phase (phase 1). There is no significant difference in the amplitude ratio of 
BAEP on the right side when compared to the left side (p >0.05). The amplitude 
changes in different phases have been depicted in the table 11 and 12. 
Table-11: Comparison of mean V/I wave amplitude ratio of BAEP in right and 
left ear in different phases of menstrual cycle 
Menstrual cycle 
phase 
Right ear (Mean±SD) Left ear (Mean±SD) 
Phase-1 0.92±0.38 0.93±0.38 
Phase-2 1.01±0.40 1.02±0.39 
Phase-3 0.90±0.43 0.90±0.42 
(P>0.05 no significant difference compared wave amplitude ratio between the 
different phases) 
 
Table-12: Comparison of mean V/I wave amplitude ratio of BAEP between right 
and left ear in different phases of menstrual cycle 
Ear Phase-1 Phase-2 Phase-3 
Right ear (Mean±SD) 0.92±0.38 1.01±0.40 0.90±0.43 
Left ear (Mean±SD) 0.93±0.38 1.02±0.39 0.90±0.42 
(P>0.05 no significant difference compared wave amplitude ratio between right 
and left ear at different phases) 
6.5.Assessment of latency changes in VEP:  
The study showed statistical significant decrease in wave P100 latency of 
visual evoked potential on the right side (p <0.05) and also in the left side (p <0.05) 
during proliferative phase (phase 2) of menstrual cycle as compared to secretory phase 
(phase 3)  and an increase in latency of the same wave during secretory phase (phase 
3) as compared to menstrual phase (phase 1).There is no significant difference in the 
latency changes of VEP on the right side when compared to the left side (p >0.05). 
The latency changes among the study group have been depicted in the table 13 and 14. 
VEP: Visual Evoked Potential         Phase -1: Menstrual phase 
Number of subjects: 80 in each phase  Phase -2: Proliferative phase                                                                                
Phase -3: Secretory phase                                                                                      
Table-13: Comparison of mean VEP wave P100 latency (ms) of right and left eye 
in different phases of menstrual cycle 
Menstrual cycle phase Right eye (Mean±SD) Left eye (Mean±SD) 
Phase-1 96.91±0.28 96.90±0.33 
Phase-2 95.26±1.08 95.19±1.29 
Phase-3 98.10±1.41* 98.00±1.47* 
(*P<0.05 significant compared Phase-2 with Phase-3) 
 
Table-14: Comparison of mean VEP wave P100 latency (ms) between right and 
left eye in different phases of menstrual cycle 
Eye Phase-1 Phase-2 Phase-3 
Right eye 
(Mean±SD) 
96.91±0.28 95.26±1.08 98.10±1.41 
Left eye 
(Mean±SD) 
96.90±0.33 95.19±1.29 98.00±1.47 
(P>0.05 no significant compared between the right and left eye in different 
phases) 
 
  
 
 
Fig.7: Comparison of mean VEP wave P100 latency (ms) of right eye in different 
phases of menstrual cycle 
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Fig.8: Comparison of mean VEP wave P100 latency (ms) of left eye in different 
phases of menstrual cycle 
 
  
  
 
 
93.5
94
94.5
95
95.5
96
96.5
97
97.5
98
PHASE 1 PHASE 2 PHASE 3
VEP Wave P100 latency Lt Eye
VEP Wave P100 latency Lt Eye 
PHASE 1
VEP Wave P100 latency Lt Eye 
PHASE 2
VEP Wave P100 latency Lt Eye 
PHASE 3
6.6.Assessment of amplitude changes in VEP:  
The study showed statistical insignificant decrease in amplitude of  visual 
evoked potential wave P100 on the right side (p >0.05) and also in the left side (p 
>0.05) during secretory phase (phase 3) as compared to proliferative phase ( phase 
2).Also showed a statistically insignificant increase in the same during proliferative 
phase ( phase 2) as compared to menstrual phase (phase 1). There is no significant 
difference in the amplitude ratio of VEP on the right side when compared to the left 
side (p >0.05). The amplitude changes in different phases have been depicted in the 
table 15 and 16. 
Table-15: Comparison of mean P100 wave amplitude of VEP in right and left eye 
in different phases of menstrual cycle 
Menstrual cycle phase Right eye (Mean±SD) Left eye (Mean±SD) 
Phase-1 7.82±0.59 7.81±0.59 
Phase-2 7.93±0.93 7.94±0.92 
Phase-3 7.72±0.79 7.73±0.79 
(P>0.05 no significant difference compared wave amplitude between the different 
phases) 
 
 
Table-16: Comparison of mean P100 wave amplitudes of VEP between right and left 
eye in different phases of menstrual cycle  
Eye Phase-1 Phase-2 Phase-3 
Right eye (Mean±SD) 7.82±0.59 7.93±0.93 7.72±0.79 
Left eye (Mean±SD) 7.81±0.59 7.94±0.92 7.73±0.79 
(P>0.05 no significant difference in wave amplitude between right and left eye in 
different phases) 
Data are represented as Mean ± SD   
VEP: Visual Evoked Potential 
 Number of subjects: 80 in each phase  
Phase -1: Menstrual phase                             
 Phase -3: Secretory phase 
Phase -2: Proliferative phase 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
7. DISCUSSION 
The present study is aimed to find out the auditory and visual evoked potential 
in young healthy females during different phases of menstrual cycle. The menstrual 
cycle is a time of many widespread changes affecting both body and mind.40,57The 
menstrual cycle influences different clinical conditions such as asthma, atopic 
dermatitis, diabetes, rheumatoid arthritis, pulmonary edema, gastrointestinal 
dysfunctions & cardiac arrhythmias .13,58,59 Neurological illnesses such as myasthenia 
gravis, multiple sclerosis,  meningioma, epilepsy, arteriovenous aneurysms, and 
migraine may be worse during the pre-menstrual phases.13 EEG also shows variations 
during different menstrual cycle phases.13,60 
 The hormonal status of a female undergo quantitative changes during 
menstrual cycle, pregnancy and menopause.40Behavioural and neurological symptoms 
like decreased concentration, nervousness, irritability, emotional instability, poor 
judgement, tension and depression are seen in women during premenstrual phase.61,62 
This may be due to the effect of gonadal hormones on neural functions.61 
 Recent studies revealed that the estrogen and progesterone have wide spread 
effects all over the central nervous system including sensory information processing in 
the brain.50 Various studies have shown that female sex hormones modulate the 
threshold, latency and amplitude of auditory, visual and taste sensations.61 
Evoked potential studies are non-invasive method to assess in real time the 
processing of sensory information in the human central as well as peripheral nervous 
system.28,63 These are electrical signals produced in response to sensory stimuli which 
are generated by the nervous system.64The evoked potential traces consist of a 
succession of waves or peaks, which reflect the neuronal responses at the different 
levels of the sensory pathways.28 By this technique we can assess the conduction times 
of the sensory impulses in the CNS.52 
Brainstem auditory evoked potentials (BAEPs) are electrical potentials 
generated in response of auditory nerve, brainstem and higher subcortical structures to 
acoustic stimulus56 and visual evoked potentials (VEPs) are the cerebral electrical 
potentials generated by the visual cortex evoked in response to visual stimulus.51 
Therefore, BAEPs and VEPs can be used both in research and in clinical practice 
toelucidate the function of the auditory and visual system .52 
Since the hormonal variation during menstrual cycle affect the sensory 
information processing in peripheral and central auditory and visual pathways, this 
study is aimed to find the effect of variation in hormones on the peripheral and central 
conduction time of auditory and visual stimuli. 63 
This study included 80 first year female nursing students of SreeMookambika 
Institute of Medical Sciences and Research Centre, Kulasekharam. This cross 
sectional study was conducted in normal healthy female subjects of age 18-25 years 
who are having regular menstrual cycle and without hearing or visual problems. The 
ovarian hormones varies during different menstrual cycle phases that is, follicular 
phase with high level of oestrogen, luteal phase with high level of progesterone and 
menstrual phase with no influence of hormones.54, 61 So to find out the variation in 
auditory and visual neural conduction in different menstrual cycle phases each subject 
was subjected to three BAEP and VEP testing within a month time. 
The present study showed a decrease in wave latencies and inter-peak latencies 
during follicular phase with a statistically significant decrease in latency of wave V 
and inter-peak latencies I-V and III-V in the oestrogen peak follicular phase and a 
statistically significant increase in the same parameters of BAEP in progesterone peak 
secretory phase. Similar results are reported by Caruso et al. and Serra et al. with a 
decrease in BAEP latencies during the periovulatory phase and they suggested that 
this may be due to the high estrogen level during this phase. High levels of estrogen 
can modulate glutamate transmission in brainstem and thereby alter the speed of 
sensory neurotransmission. This is supported by the findings of Coleman et al. 
showing a shorter BAEP latencies in estrogen treated young OVX rat and the study 
done by Sisneros et al. in female midshipman fish which showed that on treatment 
with estradiol their auditory nerves become more sensitive to male mating calls even 
during the non-breeding season.37 
 On the other hand this study is contradictory to the findings of Dehan and 
Jerger and Elkind Hirsch et al. showing longer BAEP latencies during the 
periovulartory phase. The reason they have given is that the high level of estrogen 
facilitate GABA inhibition in the auditory midbrain by increasing allopregnalone.37, 38  
Fagan and Church showed no fluctuation inBAEP latencies during the 
menstrual cycle.37 
Estrogen receptors are widely distributed in the central nervous system. Both 
ERα and ERβ are expressed in the peripheral and central auditory system of 
mammals. In many species, estrogens modulate physiological and behavioural 
responses to sensory signals, including auditory stimuli. Fluctuations in auditory 
perception and in electrophysiological measures of auditory function in menstrual 
cycle shows the importance of estrogen actions on auditory processing.65,66Estrogens 
modulate sensory processing via interactions with neurotransmitters such as 
dopamine, gamma aminobutyric acid, glutamate, and serotonin by this way it will 
affect auditory function at different levels of the CNS.65 
In the menstrual phase, during which gonadal steroids are at a low level, all the 
BAEP parameters showed a normal value that is similar to that normally found in 
males.42 
The amplitude ratio of BAEP wave V/I showed statistically insignificant 
increase in follicular phase and a decrease in secretory phase .This result is similar to 
the BAEP study in different menstrual cycle phases, done by Navpreet Mann et 
al.7Caruso et al., Khaliq et al., and Sator et al also showed an increase in BAEP peak 
amplitudes in postmenopausal women on hormone replacement therapy.27 
The peak latencies and inter-peak latencies reflect the conduction time in the 
auditory pathway. This study showed a decrease in wave latencies and inter-peak 
latencies at follicular phase reflects a faster auditory neural conduction in the estrogen 
peak phase and an increase in the same parameters during secretory phase reflects a 
slower auditory neural conduction in the progesterone peak phase. The amplitude ratio 
showed statistically insignificant increase in follicular phase and decrease in secretory 
phase. This may be due to the excitatory action of estrogen on auditory nerve fibres as 
well as CNS neurons and progesterone has the opposite effect on the CNS.  
Due to the excitatory and protective effects of estrogen in CNS, auditory 
function is found to be better in females than males and also the auditory system is 
more sensitive during high levels of estrogen in the circulation. 37 Oestrogen enhances 
synaptic transmission and improve neural conduction. Studies have shown oestrogen 
replacement treatment can decrease brainstem auditory evoked potential intervals and 
certain latencies of the Mid latency response (MLR) in postmenopausal women. 34A 
decrease in estrogen and decreased metabolism rates could affect the availability of 
neurotransmitters at the synapse and hence influence neural conduction time.42 
Estrogen can decrease the number of synaptic vesicles nearby the presynaptic 
membrane of certain inhibitory synapses. Estrogen increase neuronal excitability by 
decreasing the GABAB receptor-mediated autoinhibition of the GABAergicpreoptic 
area as well as the ability of those neurons to synthesize GABA. Progesterone 
potentiates GABA receptor activation by a nongenomic mechanism that may involve 
actions at the plasma membrane. Progesterone decrease neuronal excitability by 
formation of allopregnanolone, which is a positive modulator of GABA and it 
increases inhibitory chloride ion conductance.67 
In our study there was a statistically significant decrease in wave V latency and 
inter-peak latencies III-V and I-V during follicular phase and an increase in the same 
parameters during secretory phase .This may be due to the high influence of ovarian 
hormones on higher levels of auditory pathway. Other BAEP waves and inter-peak 
latency I-III showed statistically insignificant decrease during follicular phase and 
statistically insignificant increase in the same parameters during secretory phase. This 
may be indirectly reflects the much less effect of the ovarian hormones on lower 
levels of auditory pathway. 
 Some studies which showed similar results like our study. The study done by 
Caruso et al. showed shorter latencies of BAEP waves and interpeak intervals after 3 
months of estrogen therapy when compared to baseline. Guimaraes et al. investigated 
the auditory system of postmenopausal women who were receiving combined 
hormone treatment (Estrogen + Progesterone) and compared this group to a group 
treated only with estrogen (E) and to a control group (CG). The findings shows a 
protective effect of estradiol on the female auditory system and that the addition of 
progestin seems to have a negative influence on the peripheral and central auditory 
system.37, 38 
Broadly, estrogen seems to have more positive than negative effects to the 
auditory system. On the other hand, progestin seems to have more negative than 
positive effect on the auditory system. One possible mechanism for progesterone’s 
negative effects on hearing centers on progesterone’s ability to down regulate estrogen 
receptors in breast and uterine tissue, balancing the effects of estrogen or possible 
irreversible receptor damage.38The estrogen and other gonadal steroids act directly on 
the receptors upon the cochlea and various central auditory system pathways.  
Through other pathways they could indirectly influence central processing and also 
regulate blood flow as well as fluid electrolyte balance in the cochlea. They modulate 
the effects of neurotransmitters present along the auditory pathways.37, 42 
Estrogen has been found by some investigators as neuroprotective, and 
vasoprotective, as it is thought to produce favourable effects in axonal sprouting, 
regenerative responses, enhanced synaptic transmission and enhanced neurogenesis. 
Further its effects in direct modulation of neurotransmitter receptor functions, and 
antioxidant activities have been attributed for decrease in latency of BAEP in 
estrogenic phase.37, 68Estrogens are important in the development, maintenance and 
physiology of the CNS.14 
The visual evoked potential is defined as the electrical response arise from the 
neurons in visual cortex which is evoked by visual stimulation.51  This study showed a 
statistically significant decrease in latency of VEP wave P100 in the oestrogen peak 
follicular phase and a statistically significant increase in the same in progesterone 
peak secretory phase. This may be due to facilitating effect of estrogen on the visual 
neural conduction.55, 68  Various studies reported that estrogen cause a decrease in the 
visual transmission time by increasing the sensitivity of receptors in the optic 
pathways to dopamine. 50, 68Estrogen augments glutamate effects by binding to 
receptors that are widely present in the CNS and cause excitatory effects in the cell 
level. In addition, estrogen inhibit glutamate decarboxylase (GAD) enzyme and 
thereby the synthesis of GABA, via the widely distributed receptors in the CNS. 
When GABA synthesis is inhibited, excitatory effects become prominent and changes 
in VEP morphology and decrease in latency occurs.68From animal experiments it has 
been proven that progesterone metabolites enhance the action of gamma-
aminobutyricacid (GABA) the main inhibitory neurotransmitter in the cortex, 
producing benzodiazepine-like physiologic and behavioral effects. Estradiol has 
excitatory effects on measures of neuronal excitability, possibly acting through the 
glutamate system.69 
 Prolongation of VEP latency during the secretory phase of menstrual cycle 
probably reflects the effect of progesterone.54 There was prolongation of P100 latency 
during secretory phase also seen in studies done before by Kaned Y as well as Mohsen 
Azarmina MD and few more.53, 54, 68 Increased latency of P100 is supporting the view 
that there is effect of progesterone on neuronal conductivity. The most probable 
reasons for increased VEP latency during secretory phase may be the decrease in 
blood estrogen levels and diminution of the neuroprotective effect of estrogen and the 
vascular congestion around the optic nerve reducing conduction velocity.54 
The amplitude of VEP wave P100 showed statistically insignificant increase in 
follicular phase and a decrease in secretory phase.HikmetYilmaz et al. showed a 
similar result in VEP amplitude during menstrual cycle. 68VEP amplitude has been 
shown to be increased by estrogen directly and/or indirectly through L-type voltage-
dependent calcium channels, acetylcholine, monoamines, γ-aminobutyric acid or 
glutamate, and to be inhibited by progesterone directly and/or indirectly through γ-
aminobutyric acid or glutamate.12, 53 
The VEP parameters showed a normal value in menstrual phase, during which 
ovarian hormones are at a minimum level .This value is seems to be similar to that 
normally found in males.42  
VEPs have emerged as an important diagnostic tool in demyelinating diseases 
of the central nervous system in the current era. The clinical implication of these 
findings is in the application of VEP for confirming demyelinative disease and optic 
neuritis. In such cases one should take into account that prolongation of VEP latency 
during menstruation may erroneously verify demylinating disease. 
From the present study it has been found that the sensory neural conduction 
through the auditory and optic nerve is faster during estrogen peaked proliferative 
phase and slower during progesterone peaked secretory phase. This may be due to the 
neuronal excitatory action of the sex steroid estrogen causing a decrease in auditory 
and visual neural conduction time during proliferative phase and an increase in the 
same during secretory phase due to the inhibitory effect of progesterone. 
The study needs to be further elaborated regarding the estimation of the blood 
levels of oestrogen and progesterone in all the phases. Since the phases of menstrual 
cycle can affect the result of BAEP and VEP thus at the time of recording menstrual 
history should be taken properly and patient is in which phase is to be confirmed. 
Along with this a normative values, for the device used in the institution should be 
generated with normal healthy subjects of all age groups so possibilities of false 
reporting can be cut short. 
 
 
 
 
  
 
 
 
 
 
 
 
8.CONCLUSION 
The hearing conduction as measured by Brain Stem Auditory Evoked Potential 
(BAEP) and visual neural conduction as measured by Visual Evoked Potential (VEP) 
are better in proliferative phase as compared to secretory phase of menstrual cycle. 
The menstrual cycle phases affect hearing as well as vision due to variation in levels 
of ovarian hormones; estrogen is the likely hormone responsible for the faster 
conduction in the auditory and visual pathways. BAEP wave latencies and inter peak 
latencies as well as VEP wave latencies have important diagnostic values. The 
interpretative accuracy of the evaluation of the BAEPs and VEPs can be enhanced 
only when these normal variations are taken into consideration with relevant case 
history information.  
This study showed that normal cyclical variation in gonadal hormones 
especially estrogen and progesterone modifies the central processing of the auditory 
and visual information. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
9. SUMMARY 
The menstrual cycle is a normal phenomenon that takes place during the 
reproductive period of a female. This is manifested by monthly discharge of blood 
from the female genital tract. The hormonal variations that occur during the menstrual 
cycle affect not only the reproductive tract but also overall the body including CNS. 
These changes in CNS especially in sensory system can be detected with the help of 
evoked potential studies. 
 Hearing and vision are the most important among the sensory modalities, so 
this study is aimed to find the differences in auditory and visual neural conduction 
time in different phases of menstrual cycle. There occurs a wide variation in gonadal 
hormones during the different phases of menstrual cycle this will affect the auditory 
and visual neural conduction throughout the cycle. 
Brainstem Auditory Evoked Potential (BAEP) is an objective, low cost and 
non-invasive method of hearing assessment which detects electrical activity from the 
inner ear to the inferior colliculus.31Visual evoked potentials are the record of 
electrophysiological potential response originating from the occipital cortex by retinal 
stimulation.49 By this we can assess the functional integrity of the visual system.12 
This cross sectional study was conducted in 80 female nursing students with 
regular menstrual cycle. After getting the informed consent all subjects were subjected 
to three Brainstem Auditory Evoked Potential (BAEP) testing and Visual Evoked 
Potential (VEP) testing during three phases of their menstrual cycle namely menstrual 
(phase 1), proliferative (phase 2), and secretory (phase 3).  
From the present study, it is evident that the absolute latencies of all the waves 
of the BAEP and VEP as well as the inter-peak latencies of BAEP waves showed a 
decrease in the proliferative phase and hence, this enhanced the conduction across the 
neural pathways. On the other hand, the absolute latencies of the various BAEP and 
VEP waves as well as the inter-peak latencies of BAEP waves in the secretory phase 
were increased, which showed a slower neural conduction. The VEP amplitude and 
BAEP amplitude ratio showed an increase in proliferative phase as compared to 
secretory phase. This can be due to the excitatory and neuroprotective effect of 
oestrogen in the proliferative phase, and the antagonistic effect of progesterone in the 
secretory phase. 
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 CONSENT FORM 
PART II 
PARTICIPANTS CONSENT FORM 
 
The details of the study have been explained to me in writing and the details have 
been fully explained to me.  I am aware that the results of the study may not be 
directly beneficial to me but will help in the advancement of medical sciences. I 
confirm that I have understood the study and had the opportunity to ask questions. I 
understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without the medical care that will 
normally be provided by the hospital being affected.  I agree not to restrict the use of 
any data or results that arise from this study provided such a use is only for scientific 
purpose(s). I have been given an information sheet giving details of the study. I fully 
consent to participate in the study titled ‘A study on Auditory and Visual evoked 
potential in young healthy females during different phases of menstrual cycle.’ 
 
Serial No/Reference No : 
 
 
Name of the participant :          Address of the participant: 
 
 
 
Contact Number of the participant: 
 
Signature/Thumb impression of the  participant/Legal guardian. 
 
 
Witness: 
 
1. 
 
2. 
 
Date: 
 
Place:IMAGE 1: COMPUTERIZED RMS ALERON 401 EMG/NCV/EP 
SYSTEM 
 
 
 
                                                                   
BAEP WAVES 
 
 IMAGE 2: COMPUTERIZED RMS ALERON 401 EMG/NCV/EP 
SYSTEM 
 
 
 
 
 
                                         VEP WAVES 
 
 
11.5. ABBREVIATIONS: 
ABR  : Auditory Brainstem Response 
AEPs  : Auditory Evoked Potentials  
AVCN :  Anterior Ventral Cochlear Nucleus 
ANOVA :  Analysis Of Variance 
BAEP  :  Brainstem Auditory Evoked Potential 
BBT  :  Basal Body Temperature 
BSERs : Brainstem Evoked Responses 
CNS  :  Central Nervous System 
DCN  :  Dorsal Cochlear Nucleus 
EP  :  Evoked Potential 
ER  :  Estrogen Receptor 
FSH  :  Follicle Stimulating Hormone 
GBG  :  Gonadal Steroid Binding Globulin 
GnRH  :  Gonadotrophin Releasing Hormone 
IHEC  :  Institutional Human Ethical Committee 
IPLs  :  Inter peak Latencies 
LH  :  Leutinizing Hormone 
mm  :  Millimeter 
m-RNA :  Messenger RNA 
msec  :  Millisecond 
mV  :  Millivolt 
PSVEP :  Pattern Shift Visual Evoked Potential 
PVCN  :  Posterior Ventral Cochlear Nucleus 
SD  :  Standard Deviation 
VEP  :  Visual Evoked Potential 
 
Brainstem Auditory Evoked Potential(BAEP) 
WAVE-I latency WAVE-II latency 
Right Ear 
 
Left Ear 
 
Right Ear 
 
Left Ear 
Sl.No 
PHASE   
1 
PHASE   
2 PHASE  3 
PHASE   
1 PHASE 2 PHASE 3 
PHASE   
1 PHASE 2 PHASE 3 PHASE 1 PHASE 2 PHASE 3 
1 1.69 1.8 1.79 1.68 1.4 1.74 2.6 2.79 2.77 2.66 2.72 2.87 
2 1.65 1.7 1.77 1.69 1.64 1.78 2.8 2.5 2.89 2.78 2.76 2.85 
3 1.61 1.65 1.74 1.69 1.48 1.68 2.68 2.76 2.78 2.52 2.81 2.97 
4 1.65 1.67 1.71 1.6 1.68 1.67 2.77 2.74 2.85 2.7 2.79 2.88 
5 1.69 1.78 1.77 1.69 1.64 1.64 2.73 2.72 2.76 2.89 2.89 2.56 
6 1.69 1.69 1.75 1.69 1.63 1.68 2.76 2.76 2.78 2.52 2.76 2.76 
7 1.68 1.77 1.8 1.64 1.6 1.65 2.77 2.79 2.89 2.59 2.86 2.57 
8 1.67 1.64 1.78 1.68 1.65 1.63 2.86 2.8 2.82 2.67 2.75 2.76 
9 1.68 1.6 1.48 1.69 1.38 1.38 2.97 2.89 2.78 2.74 2.85 2.5 
10 1.69 1.62 1.79 1.66 1.7 1.76 2.79 2.76 2.86 2.52 2.76 2.6 
11 1.6 1.3 1.34 1.69 1.63 1.73 2.64 2.8 2.85 2.86 2.81 2.5 
12 1.69 1.66 1.78 1.69 1.67 1.74 2.78 2.75 2.81 2.6 2.79 2.5 
13 1.62 1.44 1.45 1.6 1.64 1.7 2.79 2.78 2.79 2.85 2.67 2.65 
14 1.64 1.71 1.75 1.69 1.69 1.72 2.8 2.75 2.86 2.78 2.74 2.94 
15 1.69 1.64 1.47 1.64 1.64 1.74 2.85 2.81 2.85 2.73 2.71 2.56 
16 1.68 1.7 1.79 1.72 1.83 1.76 2.59 2.86 2.76 2.78 2.89 2.74 
17 1.69 1.7 1.73 1.69 1.64 1.7 2.73 2.74 2.88 2.8 2.7 2.78 
18 1.63 1.44 1.74 1.69 1.63 1.74 2.78 2.74 2.87 2.78 2.8 2.56 
19 1.73 1.78 1.38 1.6 1.62 1.71 2.79 2.71 2.86 2.68 2.73 2.69 
20 1.69 1.65 1.75 1.69 1.75 1.79 2.8 2.89 2.87 2.78 2.85 2.52 
21 1.62 1.68 1.73 1.66 1.63 1.7 2.79 2.8 2.78 2.68 2.73 2.73 
22 1.69 1.67 1.76 1.7 1.39 1.72 2.86 2.7 2.87 2.75 2.77 2.73 
23 1.68 1.66 1.47 1.7 1.74 1.72 2.79 2.88 2.88 2.98 2.7 2.88 
24 1.61 1.75 1.72 1.69 1.67 1.73 2.88 2.86 2.86 2.78 2.87 2.95 
25 1.69 1.68 1.74 1.74 1.85 1.76 2.7 2.89 2.79 2.74 2.7 2.88 
26 1.63 1.68 1.74 1.69 1.78 1.8 2.75 2.88 2.99 2.88 2.8 2.76 
27 1.7 1.85 1.75 1.7 1.71 1.79 2.64 2.75 2.83 2.68 2.77 2.98 
28 1.68 1.68 1.49 1.6 1.63 1.79 2.78 2.87 2.84 2.89 2.79 2.78 
29 1.67 1.47 1.39 1.7 1.84 1.82 2.88 2.8 2.52 2.87 2.5 2.65 
30 1.69 1.6 1.7 1.8 1.81 1.8 2.97 2.88 2.65 2.9 2.76 2.94 
31 1.69 1.68 1.77 1.69 1.45 1.7 2.88 2.75 2.66 2.93 2.74 2.96 
32 1.69 1.49 1.75 1.8 1.64 1.81 2.79 2.79 2.91 2.98 2.72 2.6 
33 1.69 1.66 1.78 1.67 1.84 1.79 2.87 2.78 2.9 2.78 2.8 2.95 
34 1.6 1.66 1.71 1.8 1.82 1.72 2.66 2.76 2.87 2.52 2.81 2.94 
35 1.61 1.48 1.73 1.69 1.7 1.68 2.9 2.74 2.85 2.9 2.8 2.73 
36 1.68 1.4 1.74 1.7 1.63 1.61 2.52 2.72 2.97 2.95 2.7 2.88 
37 1.69 1.64 1.48 1.62 1.64 1.63 2.52 2.76 2.88 2.98 2.76 2.87 
38 1.69 1.48 1.78 1.73 1.8 1.64 2.89 2.81 2.56 2.96 2.8 2.73 
39 1.69 1.68 1.77 1.63 1.69 1.64 2.52 2.79 2.76 2.97 2.8 2.8 
40 1.69 1.64 1.44 1.8 1.82 1.7 2.59 2.89 2.57 2.8 2.85 2.76 
41 1.69 1.63 1.78 1.61 1.63 1.63 2.67 2.76 2.76 2.79 2.77 2.88 
42 1.75 1.6 1.45 1.63 1.6 1.64 2.74 2.86 2.5 2.78 2.81 2.66 
43 1.68 1.65 1.73 1.6 1.8 1.6 2.52 2.75 2.6 2.88 2.8 2.68 
44 1.69 1.38 1.38 1.7 1.84 1.8 2.9 2.85 2.5 2.85 2.8 2.96 
45 1.66 1.7 1.76 1.64 1.68 1.67 2.6 2.76 2.5 2.9 2.74 2.86 
46 1.69 1.63 1.43 1.69 1.8 1.69 2.85 2.81 2.65 2.73 2.79 2.84 
47 1.69 1.67 1.74 1.65 1.7 1.67 2.79 2.79 2.94 2.78 2.5 2.89 
48 1.6 1.64 1.7 1.61 1.65 1.64 2.73 2.67 2.56 2.6 2.76 2.77 
49 1.69 1.69 1.42 1.69 1.67 1.61 2.79 2.74 2.74 2.8 2.74 2.89 
50 1.64 1.64 1.74 1.69 1.78 1.67 2.8 2.71 2.78 2.68 2.72 2.78 
51 1.72 1.83 1.76 1.69 1.69 1.65 2.97 2.89 2.56 2.77 2.76 2.85 
52 1.69 1.64 1.7 1.68 1.77 1.8 2.68 2.7 2.69 2.73 2.79 2.76 
53 1.69 1.63 1.44 1.7 1.64 1.78 2.78 2.8 2.52 2.76 2.8 2.78 
54 1.69 1.62 1.71 1.68 1.6 1.78 2.68 2.73 2.73 2.77 2.89 2.89 
55 1.69 1.75 1.49 1.69 1.62 1.69 2.75 2.85 2.73 2.86 2.76 2.82 
56 1.7 1.63 1.7 1.69 1.3 1.34 2.98 2.73 3.02 2.97 2.8 2.78 
57 1.7 1.39 1.42 1.69 1.66 1.68 2.78 2.77 2.95 2.79 2.75 2.86 
58 1.7 1.74 1.72 1.73 1.44 1.65 2.74 2.7 2.88 2.64 2.78 2.85 
59 1.69 1.67 1.73 1.64 1.71 1.65 2.88 2.87 2.76 2.95 2.75 2.81 
60 1.74 1.85 1.76 1.69 1.64 1.67 2.68 2.7 2.8 2.97 2.81 2.79 
61 1.69 1.78 1.8 1.68 1.7 1.69 2.89 2.8 2.78 2.8 2.86 2.86 
62 1.7 1.71 1.79 1.69 1.7 1.63 2.87 2.77 2.79 2.85 2.74 2.85 
63 1.6 1.63 1.79 1.63 1.44 1.64 2.9 2.79 2.94 2.59 2.74 2.94 
64 1.75 1.84 1.82 1.73 1.78 1.69 2.93 2.5 2.96 2.73 2.71 2.88 
65 1.8 1.81 1.8 1.69 1.65 1.65 2.98 2.76 2.9 2.78 2.89 2.87 
66 1.69 1.45 1.7 1.62 1.68 1.63 2.78 2.74 2.95 2.79 2.8 2.86 
67 1.8 1.64 1.81 1.68 1.67 1.66 2.52 2.72 2.94 2.8 2.7 2.87 
68 1.78 1.84 1.79 1.7 1.66 1.67 2.9 2.8 2.73 2.79 2.88 2.97 
69 1.8 1.82 1.82 1.61 1.75 1.62 2.95 2.81 2.88 2.86 2.86 2.87 
70 1.69 1.7 1.78 1.68 1.68 1.64 2.79 2.8 2.87 2.79 2.78 2.88 
71 1.7 1.63 1.71 1.63 1.68 1.64 2.96 2.7 2.73 2.88 2.88 2.86 
72 1.62 1.64 1.73 1.7 1.85 1.65 2.97 2.76 2.78 2.87 2.75 2.8 
73 1.73 1.8 1.74 1.68 1.68 1.69 2.8 2.8 2.76 2.75 2.87 2.8 
74 1.63 1.69 1.74 1.67 1.67 1.67 2.77 2.8 2.88 2.64 2.8 2.83 
75 1.8 1.82 1.81 1.69 1.6 1.6 2.78 2.85 2.66 2.76 2.7 2.84 
76 1.61 1.63 1.73 1.69 1.68 1.67 2.88 2.77 2.68 2.88 2.75 2.6 
77 1.63 1.6 1.74 1.69 1.49 1.65 2.85 2.81 2.96 2.79 2.79 2.65 
78 1.6 1.8 1.7 1.69 1.66 1.68 2.9 2.8 2.86 2.79 2.78 2.66 
79 1.6 1.84 1.8 1.6 1.66 1.61 2.73 2.8 2.84 2.79 2.76 2.91 
80 1.64 1.68 1.77 1.7 1.48 1.63 2.78 2.74 2.89 2.87 2.74 2.9 
 
  
  
Brainstem Auditory Evoked Potential(BAEP) 
 
WAVE-III latency 
 
WAVE-IV latency 
 
Right Ear 
 
Left Ear 
 
Right Ear 
 
Left Ear 
Sl.No 
PHASE  
1 
PHASE  
2 PHASE  3 
PHASE  
1 PHASE  2 PHASE  3 PHASE 1 PHASE 2 PHASE 3 PHASE 1 
 
PHASE 
 2 
PHASE 3 
1 3.54 3.5 3.69 3.94 3.67 3.52 5.2 4.52 4.62 5.08 4.98 5.06 
2 3.75 3.5 3.54 3.74 3.66 3.35 5.08 5.06 4.98 5.06 4.97 4.99 
3 3.5 3.59 3.69 3.69 3.94 3.72 5.32 5.2 4.94 4.77 4.98 4.77 
4 3.5 3.55 3.67 3.63 3.55 3.74 4.98 5.08 5.2 5.08 4.94 4.73 
5 3.94 3.57 3.63 3.55 3.57 3.67 5.2 5.08 5.79 5.02 5.08 5.08 
6 3.68 3.65 3.67 3.71 3.56 3.67 5.22 5.23 5.76 5 5.08 5.08 
7 3.66 3.56 3.68 3.72 3.57 3.7 4.94 4.87 5.65 4.94 5.06 5.08 
8 3.63 3.94 3.66 3.67 3.94 3.74 5.08 4.98 5.88 4.88 4.98 5.2 
9 3.55 3.57 3.72 3.55 3.7 3.74 5.06 4.94 5.73 4.52 4.6 4.81 
10 3.71 3.59 3.67 3.56 3.55 3.71 5.34 5.08 5.68 5.06 4.73 4.77 
11 3.72 3.59 3.72 3.65 3.59 3.35 5.08 5.08 5.75 4.9 4.08 5.32 
12 3.67 3.57 3.74 3.55 3.51 3.71 5.02 5.06 5.08 5.08 4.08 4.94 
13 3.68 3.68 3.68 3.65 3.57 3.65 5.1 4.99 5.95 4.56 4.08 4.83 
14 3.66 3.7 3.69 3.69 3.69 3.74 4.94 4.77 5.81 4.94 4.99 4.77 
15 3.73 3.55 3.68 3.64 3.72 3.71 5 4.73 5.8 4.81 4.81 5 
16 3.66 3.56 3.69 3.75 3.55 3.67 5.12 5.08 5.73 4.81 4.87 4.85 
17 3.65 3.51 3.67 3.66 3.54 3.5 5.06 5.08 5.95 5.06 4.42 5.02 
18 3.66 3.56 3.65 3.92 3.5 3.52 4.9 5.08 5.56 4.98 4.94 4.5 
19 3.64 3.7 3.74 3.55 3.51 3.7 5.08 4.5 5.77 5.08 5.56 5.06 
20 3.75 3.51 3.71 3.67 3.54 3.71 4.99 4.81 5.88 5.3 5.77 4.99 
21 3.54 3.55 3.67 3.72 3.94 3.74 4.94 4.77 5.85 4.98 4.98 5.06 
22 3.92 3.67 3.68 3.69 3.94 3.67 4.93 5.52 5.02 4.85 4.62 4.87 
23 3.55 3.59 3.66 3.68 3.59 3.6 4.81 5.95 5.06 5.02 4.98 5.08 
24 3.67 3.7 3.7 3.72 3.55 3.35 5.06 5.83 5.06 5.34 4.94 5.08 
25 3.56 3.59 3.71 3.75 3.53 3.74 4.5 5.77 4.52 5.08 5.08 4.98 
26 3.58 3.72 3.74 3.66 3.55 3.69 5.08 5 5.06 5.11 4.79 4.97 
27 3.56 3.94 3.67 3.65 3.9 3.74 4.8 5.85 5.2 4.78 5.06 4.98 
28 3.58 3.69 3.6 3.75 3.66 3.69 4.96 5.02 5.08 5.32 4.97 4.94 
29 3.59 3.65 3.66 3.67 3.65 3.58 4.98 5.06 5.08 4.99 5.1 5.08 
30 3.65 3.66 3.74 3.5 3.67 3.63 5.02 5.06 4.52 4.77 4.73 5.08 
31 3.75 3.65 3.69 3.55 3.65 3.52 4.99 4.52 4.87 5.08 5.08 5.06 
32 3.55 3.9 3.74 3.59 3.6 3.35 5.08 5.06 4.98 5.06 4.75 4.98 
33 3.75 3.66 3.69 3.69 3.94 3.72 4.9 4.87 4.94 4.77 5.08 5.31 
34 3.56 3.65 3.7 3.63 3.58 3.74 5.3 5.08 5.08 5.08 5.3 4.73 
35 3.66 3.69 3.63 3.55 3.44 3.67 5.02 5.08 5.08 5.02 5 4.7 
36 3.94 3.67 3.52 3.71 3.59 3.67 5.31 4.98 5.06 4.87 5.6 4.5 
37 3.74 3.66 3.35 3.57 3.57 3.7 4.77 4.97 4.99 4.94 4.87 4.67 
38 3.69 3.94 3.72 3.67 3.94 3.74 5.08 4.98 4.77 4.98 4.94 4.99 
39 3.63 3.55 3.74 3.48 3.9 3.74 5.06 4.94 4.73 5.21 5.3 4.81 
40 3.55 3.57 3.67 3.5 3.52 3.71 4.77 5.08 5.08 5.06 4.77 4.87 
41 3.71 3.56 3.67 3.73 3.44 3.35 5.08 5.08 5.08 4.9 5.11 4.5 
42 3.72 3.57 3.7 3.66 3.51 3.71 5.02 5.06 5.08 5.08 4.85 4.94 
43 3.67 3.94 3.74 3.55 3.57 3.65 5 4.98 5.2 4.99 5.02 4.9 
44 3.55 3.7 3.74 3.68 3.9 3.74 4.94 4.6 4.81 5.2 5.06 4.77 
45 3.56 3.55 3.71 3.55 3.59 3.71 4.88 4.73 4.77 5.08 5.06 4.98 
46 3.65 3.59 3.35 3.54 3.5 3.69 4.52 4.08 5.32 5.32 4.52 4.62 
47 3.55 3.51 3.71 3.75 3.5 3.68 5.06 4.08 4.94 4.98 5.06 4.98 
48 3.65 3.57 3.65 3.5 3.59 3.69 4.9 4.08 4.83 5.2 5.2 4.94 
49 3.69 3.9 3.74 3.5 3.55 3.67 5.08 4.99 4.77 5.22 5.08 5.2 
50 3.64 3.72 3.71 3.94 3.57 3.63 4.56 4.81 5 4.94 5.08 5.79 
51 3.75 3.55 3.67 3.68 3.65 3.67 4.94 4.87 4.85 5.08 5.23 5.76 
52 3.66 3.54 3.5 3.66 3.56 3.68 4.81 4.42 5.02 5.06 4.87 5.65 
53 3.92 3.5 3.52 3.63 3.94 3.66 4.81 4.94 4.5 5.34 4.98 5.88 
54 3.55 3.51 3.7 3.55 3.57 3.72 5.06 5.56 5.06 5.08 4.94 5.73 
55 3.67 3.54 3.71 3.71 3.59 3.67 4.98 5.77 4.99 5.02 5.08 5.68 
56 3.72 3.94 3.74 3.72 3.59 3.72 5.08 4.98 5.06 5.1 5.08 5.75 
57 3.69 3.94 3.67 3.67 3.57 3.74 5.3 4.62 4.87 4.94 5.06 5.08 
58 3.68 3.59 3.6 3.68 3.68 3.68 4.98 4.98 5.08 5 4.99 5.95 
59 3.72 3.55 3.35 3.66 3.7 3.69 4.85 4.94 5.08 5.12 4.77 5.81 
60 3.75 3.53 3.74 3.73 3.55 3.7 5.02 5.08 4.98 5.06 4.73 5.8 
61 3.66 3.55 3.69 3.66 3.56 3.69 5.34 4.79 4.97 4.9 5.08 5.73 
62 3.65 3.9 3.74 3.65 3.51 3.67 5.08 5.06 4.98 5.08 5.08 5.95 
63 3.75 3.66 3.69 3.66 3.56 3.65 5.11 4.97 4.94 4.99 5.08 5.56 
64 3.67 3.65 3.58 3.64 3.7 3.74 4.78 5.1 5.08 4.94 4.5 5.77 
65 3.5 3.67 3.63 3.75 3.51 3.71 5.32 4.73 5.08 4.93 4.81 5.88 
66 3.55 3.65 3.52 3.54 3.55 3.67 4.99 5.08 5.06 4.81 4.77 5.85 
67 3.59 3.6 3.35 3.92 3.67 3.68 4.77 4.75 4.98 5.06 5.52 5.02 
68 3.69 3.94 3.72 3.66 3.59 3.66 5.08 5.08 5.31 4.5 5.95 5.06 
69 3.63 3.58 3.74 3.67 3.7 3.7 5.06 5.3 4.73 5.08 5.83 5.06 
70 3.55 3.44 3.67 3.56 3.59 3.71 4.77 5 4.7 4.8 5.77 4.52 
71 3.71 3.59 3.67 3.58 3.72 3.74 5.08 5.6 4.5 4.96 5 5.06 
72 3.57 3.57 3.7 3.67 3.94 3.67 5.02 4.87 4.67 4.98 5.85 5.2 
73 3.67 3.94 3.74 3.58 3.69 3.6 4.87 4.94 4.99 5.02 5.02 5.08 
74 3.48 3.9 3.74 3.59 3.65 3.66 4.94 5.3 4.81 4.99 5.06 5.08 
75 3.5 3.52 3.71 3.65 3.66 3.74 4.98 4.77 4.87 5.08 5.06 4.52 
76 3.73 3.44 3.35 3.75 3.65 3.69 5.21 5.11 4.5 5.2 4.52 4.87 
77 3.66 3.51 3.71 3.65 3.9 3.74 5.06 4.85 4.94 4.99 5.06 4.98 
78 3.55 3.57 3.65 3.75 3.66 3.69 4.9 5.02 4.9 5.02 4.87 4.94 
79 3.68 3.9 3.74 3.56 3.65 3.7 5.08 5.06 4.77 5.31 5.08 5.08 
80 3.55 3.59 3.71 3.66 3.64 3.63 4.99 5.06 4.98 4.77 5.08 5.08 
 
  
 Brainstem Auditory Evoked Potential(BAEP) 
 
WAVE-V Latency 
 
INTERPEAK Latency I-III 
 
Right Ear 
 
Left Ear 
 
Right Ear 
 
Left Ear 
Sl.No PHASE 1 PHASE  2 PHASE 3 PHASE 1 PHASE 2 PHASE 3 PHASE 1 PHASE  2 PHASE 3 
PHASE  
1 
PHASE  
2 
PHASE  3 
1 6.22 5.4 6.01 6.23 5.44 6.4 1.94 1.96 2.35 1.92 1.96 1.71 
2 6.32 5.49 6.15 5.88 5.21 5.97 1.96 1.98 2.08 2.4 1.98 1.96 
3 6.21 5.35 6.3 5.4 5.4 6.02 1.83 1.99 1.71 1.74 1.99 2.4 
4 6.2 5.42 5.89 5.67 5.23 5.5 1.98 1.48 2.04 2.33 1.48 2.44 
5 6.03 5.4 6.35 5.21 5.59 5.87 1.99 1.93 2.35 2.52 1.93 2.48 
6 6.012 6 5.95 5.44 5.4 5.88 1.85 1.95 1.35 2.52 1.95 2.08 
7 5.98 5.11 6.02 5.27 5.4 6.15 1.68 1.75 2.35 1.85 1.75 2.1 
8 5.88 5.69 5 5.31 5.35 6.12 1.97 2.48 2.52 1.83 2.48 2 
9 6.06 5.49 6.01 5.4 5.02 6 1.92 1.99 1.65 1.85 1.99 2 
10 6.03 5.3 6.22 5.44 5.23 5.78 2.4 1.98 2 1.62 1.98 1.35 
11 5.99 5.44 5.99 5.77 5.53 5.99 1.74 1.82 1.69 1.85 1.82 1.35 
12 5.87 6.19 5.93 6.21 5.35 5.4 1.89 1.8 2.33 2.42 1.8 1.94 
13 5.96 5.4 5.56 5.21 5.69 6.48 2.52 1.99 2.52 1.88 1.99 1.94 
14 5.94 5.6 5.93 5.52 5.53 6.21 2.52 1.96 2 1.92 1.96 1.56 
15 5.87 5.44 5.4 5.44 5.51 5.6 1.85 2 1.58 1.94 2 1.9 
16 5.77 5.31 6.21 5.81 5.51 6.23 1.83 1.75 1.71 1.92 1.75 2.35 
17 6.21 5 5.99 6.21 6.19 5.2 1.85 1.95 1.96 2.08 1.95 2.08 
18 6.32 6.21 5.89 6.15 5.4 5.56 1.62 1.65 2.4 1.89 1.65 1.71 
19 6.21 5.34 5.78 5.9 5.6 5.4 1.85 1.98 2.44 1.62 1.98 2.04 
20 6 5.48 5.56 5.73 5.21 6.21 2.42 1.75 2.48 1.83 1.75 2.35 
21 5.81 5.48 5.21 5.21 5.31 6.27 1.88 1.96 2.08 1.96 1.96 1.35 
22 6.21 5.52 5.11 5.94 5.69 6.21 1.92 1.98 2.1 1.96 1.98 2.35 
23 6.15 5.69 5.23 5.56 6.21 5.23 1.94 1.75 2 2.04 1.75 2.52 
24 5.9 5.23 5.2 5.35 6.02 5.4 1.92 1.95 2 2.08 1.95 1.65 
25 5.73 5.59 6.1 5.21 5.48 5.56 2.08 2.4 1.35 1.83 2.4 2 
26 5.21 5.44 6.4 5.65 5.98 6.21 1.89 1.93 1.35 2.19 1.93 1.69 
27 5.94 5.21 5.97 5.27 5.52 5.21 1.62 1.95 1.94 2.29 1.95 2.33 
28 5.56 5.4 6.02 6.21 5.69 6.23 1.83 1.9 1.94 1.85 1.9 2.52 
29 5.35 5.23 5.73 5.23 5.23 6.21 1.96 1.94 1.56 1.68 1.94 2 
30 5.21 5.59 5.87 5.23 5.69 6.21 1.96 1.88 1.9 2.08 1.88 1.58 
31 5.65 5.4 5.88 5.21 5.44 6.23 2.04 1.96 2.35 1.92 1.96 1.71 
32 6.23 5.03 6.15 5.4 6.21 6.2 2.08 1.96 2.08 2.4 1.96 1.96 
33 6.21 5.35 6.12 5.4 5.4 6.02 1.83 1.97 1.71 1.74 1.97 2.4 
34 6.23 5.02 6 5.38 5.23 6.3 2.19 1.48 2.04 2.33 1.48 2.44 
35 6.11 5.23 5.78 5.21 5.69 6.98 2.29 2.22 2.35 2.52 2.22 2.48 
36 6.23 5.53 5.99 5.44 5.4 6.87 1.85 1.95 1.35 2.52 1.95 2.35 
37 5.4 5.35 5.4 5.27 5.88 6.15 1.68 1.75 2.35 1.85 1.75 2.08 
38 5.4 5.69 6.48 5.31 5.87 6.03 2.08 2.48 2.52 1.83 2.48 1.71 
39 6.06 5.53 6.21 5.4 5.49 6.32 1.92 2.21 1.65 1.85 2.21 2.04 
40 5.21 5.51 5.6 5.44 5.67 6.02 2.4 2.35 2 1.62 2.35 2.35 
41 5.44 5.51 6.23 5.77 5.89 5.32 1.74 2.35 1.69 1.85 2.35 1.35 
42 5.27 6.19 5.2 5.42 5.46 5.89 2.33 2.48 2.33 2.42 2.48 2.35 
43 5.31 5.4 5.56 5.21 5.69 5.48 2.52 2.17 2.52 1.94 2.17 2.52 
44 5.4 5.6 5.4 5.52 5.8 5.88 2.52 2.21 2 1.96 2.21 1.65 
45 5.44 5.21 6.21 5.44 6.2 6.11 1.85 2 1.58 1.83 2 2 
46 5.77 5.31 6.27 6.22 5.03 5.99 1.83 1.75 1.71 1.98 1.75 1.69 
47 6.21 5.69 6.21 6.32 5.19 6 1.85 2.08 1.96 1.99 2.08 2.33 
48 5.21 6.21 5.23 6.21 5.4 6.12 1.62 1.65 2.4 1.85 1.65 2.52 
49 5.52 6.02 5.4 6.2 5 5.9 1.85 2 2.44 1.68 2 2 
50 5.44 5.48 5.56 6.03 5.2 6.2 2.42 1.75 2.48 1.97 1.75 1.58 
51 5.81 5.98 6.21 6.012 5.11 6.3 1.88 2.35 2.08 1.92 2.35 1.71 
52 6.21 5.52 5.21 5.98 5.59 5.99 1.92 1.98 2.1 2.4 1.98 1.96 
53 6.15 5.69 6.23 5.88 5.21 6 1.94 1.75 2 1.74 1.75 2.4 
54 5.9 5.23 6.21 6.06 5 5.4 1.92 2.08 2 1.89 2.08 2.44 
55 5.73 5.69 6.21 6.03 6.22 6.2 2.08 2.4 1.35 2.52 2.4 2.48 
56 5.21 5.44 6.23 5.99 5.4 6.01 1.89 2.21 1.35 2.52 2.21 2.08 
57 5.94 6.21 6.2 5.87 5.49 6.15 1.62 2.29 1.94 1.85 2.29 2.1 
58 5.56 5.4 6.02 5.96 5.35 6.3 1.83 2.52 1.94 1.83 2.52 2 
59 5.35 5.23 6.3 5.94 5.42 5.89 1.96 1.94 1.56 1.85 1.94 2 
60 5.21 5.69 6.98 5.87 5.4 6.35 1.96 2.21 1.9 1.62 2.21 1.35 
61 5.65 5.4 6.87 5.77 6 5.95 2.04 1.96 2.35 1.85 1.96 1.35 
62 5.27 5.88 6.15 6.21 5.11 6.02 2.08 2.25 2.08 2.42 2.25 1.94 
63 6.21 5.87 6.03 6.32 5.69 5 1.83 2.04 1.71 1.88 2.04 1.94 
64 5.7 5.49 6.32 6.21 5.49 6.01 2.19 1.48 2.04 1.92 1.48 1.56 
65 5.23 5.67 6.02 6 5.3 6.22 2.29 1.93 2.35 1.94 1.93 1.9 
66 5.76 5.89 5.32 5.81 5.44 5.99 1.85 1.95 1.35 1.92 1.95 2.35 
67 5.4 5.46 5.89 5.8 6.19 5.93 1.68 1.75 2.35 2.08 1.75 2.08 
68 5.4 5.69 5.48 6.15 5.4 5.56 2.08 2.48 2.52 1.89 2.48 1.71 
69 5.38 5.8 5.88 5.9 5.6 5.93 1.92 1.94 1.65 1.62 1.94 2.04 
70 5.21 6.2 6.11 5.73 5.88 5.4 2.4 1.97 2 1.9 1.97 2.35 
71 5.44 5.03 5.99 5.21 5.31 6.21 1.74 1.98 1.69 1.96 1.98 1.35 
72 5.27 5.19 6 5.94 5 5.99 2.33 1.8 2.33 1.96 1.9 2.35 
73 5.31 5.4 6.12 5.99 6.21 5.89 2.52 1.96 2.52 2.04 1.96 1.88 
74 5.4 5 5.9 5.55 5.34 5.3 2.52 1.99 2 2.08 1.99 1.65 
75 5.44 5.2 6.2 5.21 5.48 5.56 1.85 1.96 1.58 1.83 1.96 2 
76 5.77 5.11 6.3 5.65 5.48 5.21 1.83 1.94 1.71 2.19 1.94 1.69 
77 5.42 5.59 5.99 6.23 5.52 5.11 1.85 1.96 1.96 2.29 1.96 2.33 
78 5.21 5.21 6 6.21 5.69 5.23 1.62 1.65 2.4 1.85 1.65 2.52 
79 5.52 5 5.4 6.23 5.23 5.2 1.85 2 2.44 1.68 2 2 
80 5.44 6.22 6.2 6.11 5.59 6.1 2.42 1.75 2.48 2.08 1.75 1.58 
 
  
 Brainstem Auditory Evoked Potential(BAEP) 
 
INTERPEAK latency III-V 
 
INTERPEAK latency I-V 
 
Right Ear 
 
Left Ear 
 
Right Ear 
 
Left Ear 
Sl.No PHASE 1 PHASE 2 PHASE  3 PHASE 1 PHASE 2 
PHASE  
3 PHASE 1 PHASE 2 PHASE 3 PHASE 1 PHASE 2 PHASE    3 
1 2.1 1.54 2.32 2.13 1.58 2 4.15 3.79 4.32 3.99 3.79 3.81 
2 2 2.23 2.25 1.78 1.87 2.88 4.33 3.88 3.99 3.23 3.21 3.98 
3 2.48 1.75 2.4 1.67 1.77 2.1 4.23 4.5 3.23 3.77 4.75 4.15 
4 1.75 1.63 2.34 1.97 2.42 1.97 4.29 3.81 3.77 4.15 3.98 4.15 
5 2.32 2.21 1.9 2.11 1.46 2.32 4.99 4.65 4.15 3.5 4.19 4.33 
6 2.12 1.88 2.35 1.98 1.67 1.93 4.89 3.82 3.5 3.27 3.21 4.23 
7 2.04 2 2.4 1.77 1.85 1.97 4.98 3.86 4.27 3.54 3.33 4.29 
8 2.1 1.96 1.99 2.42 1.5 1.83 4.06 4.04 4.54 3.35 3.69 3.99 
9 2.13 2.22 2.36 2.4 2.33 1.99 3.88 3.78 4.45 3.81 3.21 3.89 
10 2 2.04 1.97 1.86 2.69 2.32 3.86 3.79 4.81 3.98 3.02 3.98 
11 2.01 1.77 1.96 1.58 2.67 2.21 3.97 3.21 4.98 4.15 3.03 4.06 
12 1.88 2.42 1.8 2.08 1.63 1.97 3.82 4.75 4.15 4.52 3.25 3.88 
13 1.94 2.34 2.12 2.04 2.38 2.02 4.15 3.98 4.52 3.79 3.52 3.86 
14 2.2 1.99 1.95 2.81 1.6 1.69 3.91 4.19 3.79 3.97 3.69 3.97 
15 1.87 1.85 2.35 2.79 1.75 2.22 3.95 3.77 3.97 4.3 3.5 3.82 
16 2.42 1.87 2.36 2 1.58 1.95 3.96 3.84 4.3 4.27 4.04 4.15 
17 2.4 2.33 2.37 1.92 1.96 2.12 3.85 3.83 4.27 4.23 3.71 4.91 
18 1.98 2.69 2.22 1.93 1.92 1.88 3.81 4.21 4.23 3.96 4.21 4.95 
19 1.87 2.67 2.31 2 2.69 2.34 3.98 4.02 3.96 4.02 3.88 4.96 
20 2.08 1.99 2.22 1.63 2.04 2.08 4.15 4.04 4.02 3.89 3.63 4.85 
21 2.04 2.38 2.31 2 1.67 2.17 4.52 4.25 3.89 3.99 4.08 4.81 
22 2.81 1.85 1.97 1.97 2.13 1.9 3.79 3.88 3.99 4.15 4.88 4.98 
23 2.79 1.75 2.11 1.71 2.22 2 3.97 3.69 4.15 4.33 4.98 4.15 
24 2 1.58 1.98 2.21 2.31 1.88 4.21 3.82 4.33 3.96 4.87 4.52 
25 1.92 1.96 1.85 2.48 1.75 2.12 4.25 4.04 3.96 3.97 4.97 3.79 
26 1.98 1.92 1.88 2 2.24 1.99 3.91 3.71 3.97 3.9 4.98 3.97 
27 2 2.69 2.34 2.22 1.29 2.33 3.95 4.21 3.9 4.25 4.99 4.21 
28 1.87 2.04 2.08 2.24 1.88 2.32 4.02 3.88 4.25 3.98 4 4.25 
29 2 1.99 2.17 2.04 2 2.36 3.73 3.63 3.98 4.06 4.04 3.91 
30 2.32 2.13 2.21 1.99 1.96 1.98 3.98 4.08 4.06 3.87 4.96 3.95 
31 1.71 2.34 2.3 2.13 2.11 1.99 4.15 3.9 3.87 3.99 4.94 4.02 
32 1.98 1.38 2.25 2.33 1.99 1.35 4.33 3.89 3.99 3.98 3.98 3.73 
33 2.48 1.75 2.98 2.13 1.77 1.98 3.86 4.23 3.98 4.3 3.76 3.98 
34 1.87 1.63 2.35 1.99 2.42 1.1 3.88 3.81 4.3 4.15 3.98 4.15 
35 1.99 1.29 2.36 2 2 1.36 3.9 3.87 4.15 4.25 4.19 4.33 
36 1.69 1.88 2.88 2.23 2.1 1.95 4.24 4.11 4.25 4.2 4.21 4 
37 2.04 2 2.36 2.1 2.31 2.37 3.98 3.76 3.9 4 3.97 3.88 
38 1.95 1.96 2.97 2.42 2.43 1.83 4.06 4.04 3.86 4.26 3.89 3.9 
39 2.13 1.58 2 2.4 2.33 2.4 4.32 3.75 4.26 3.81 4.21 4.24 
40 1.78 1.87 2.88 1.94 2.69 1.89 3.99 3.79 3.81 3.98 4.02 3.98 
41 1.67 1.77 2.1 1.99 2.67 2.4 3.23 3.21 3.98 4.15 4.04 4.06 
42 1.97 2.42 1.97 2.08 1.63 2.24 3.77 4.75 4.15 4.15 3.79 4.32 
43 2.11 1.46 2.32 2.1 1.54 2.32 4.15 3.98 4.15 4.33 3.88 3.99 
44 1.98 1.67 1.93 2 2.23 2.25 3.5 4.19 4.33 4.23 4.5 3.23 
45 1.77 1.85 1.97 2.48 1.75 2.4 3.27 3.21 4.23 4.29 3.81 3.77 
46 2.42 1.5 1.83 1.75 1.63 2.34 3.54 3.33 4.29 4.99 4.65 4.15 
47 2.4 2.33 1.99 2.32 2.21 1.9 3.35 3.69 3.99 4.89 3.82 3.5 
48 1.86 2.69 2.32 2.12 1.88 2.35 3.81 3.21 3.89 4.98 3.86 4.27 
49 1.58 2.67 2.21 2.04 2 2.4 3.98 3.02 3.98 4.06 4.04 4.54 
50 2.08 1.63 1.97 2.1 1.96 1.99 4.15 3.03 4.06 3.88 3.78 4.45 
51 2.04 2.38 2.02 2.13 2.22 2.36 4.52 3.25 3.88 3.86 3.79 4.81 
52 2.81 1.6 1.69 2 2.04 1.97 3.79 3.52 3.86 3.97 3.21 4.98 
53 2.79 1.75 2.22 2.01 1.77 1.96 3.97 3.69 3.97 3.82 4.75 4.15 
54 2 1.58 1.95 1.88 2.42 1.8 4.3 3.5 3.82 4.15 3.98 4.52 
55 1.92 1.96 2.12 1.94 2.34 2.12 4.27 4.04 4.15 3.91 4.19 3.79 
56 1.93 1.92 1.88 2.2 1.99 1.95 4.23 3.71 4.91 3.95 3.77 3.97 
57 2 2.69 2.34 1.87 1.85 2.35 3.96 4.21 4.95 3.96 3.84 4.3 
58 1.63 2.04 2.08 2.42 1.87 2.36 4.02 3.88 4.96 3.85 3.83 4.27 
59 2 1.67 2.17 2.4 2.33 2.37 3.89 3.63 4.85 3.81 4.21 4.23 
60 1.97 2.13 1.9 1.98 2.69 2.22 3.99 4.08 4.81 3.98 4.02 3.96 
61 1.71 2.22 2 1.87 2.67 2.31 4.15 4.88 4.98 4.15 4.04 4.02 
62 2.21 2.31 1.88 2.08 1.99 2.22 4.33 4.98 4.15 4.52 4.25 3.89 
63 2.48 1.75 2.12 2.04 2.38 2.31 3.96 4.87 4.52 3.79 3.88 3.99 
64 2 2.24 1.99 2.81 2 1.97 3.97 4.97 3.79 3.97 3.69 4.15 
65 2.22 1.29 2.33 2.79 1.75 2.11 3.9 4.98 3.97 4.21 3.82 4.33 
66 2.24 1.88 2.32 2.2 1.58 1.98 4.25 4.99 4.21 4.25 4.04 3.96 
67 2.04 2 2.36 1.92 1.96 1.85 3.98 4 4.25 3.91 3.71 3.97 
68 1.99 1.96 1.98 1.98 1.92 2 4.06 4.04 3.91 3.95 4.21 3.9 
69 2.13 2.11 1.99 2.1 2.69 2.34 3.87 4.96 3.95 4.02 3.88 4.25 
70 2.33 1.99 1.35 1.87 2.04 2.08 3.99 4.94 4.02 3.73 3.63 3.98 
71 2.13 1.77 1.98 2 1.99 2.17 3.98 3.98 3.73 4 4.08 4.06 
72 1.99 2.42 1.1 2.32 2.13 2.21 4.3 3.76 3.98 4.15 3.9 3.87 
73 2 2 1.36 1.71 2.34 2.3 4.15 3.98 4.15 4.33 3.89 3.99 
74 2.23 2.1 1.95 1.98 1.38 2.25 4.25 4.19 4.33 3.86 3.88 3.98 
75 2.1 2.31 2.37 2.48 1.75 2.98 4.2 4.21 4 3.88 3.81 4.3 
76 2.42 2.43 1.83 1.87 1.63 2.35 4 3.97 3.88 3.9 3.87 4.15 
77 2.4 2.33 2.4 1.99 1.29 2.36 4.26 3.89 3.9 4.24 4.11 4.25 
78 1.94 2.69 1.89 1.69 1.88 2.88 3.81 4.21 4.24 3.98 3.76 4.23 
79 1.99 2.67 2.4 2.04 2 2.36 3.98 4.02 3.98 4.06 4.04 3.86 
80 2.08 1.63 2.24 1.95 1.96 2.97 4.15 4.04 4.06 4.32 3.75 4.26 
 
  
 
Brainstem Auditory Evoked Potential(BAEP) 
 
AMPLITUDE Ratio (V/I) 
 
AMPLITUDE Ratio (V/I) 
 
Right Ear 
 
Left Ear 
 
Right Ear 
 
Left Ear 
Sl.No PHASE 1 
PHASE 
2 PHASE 3 PHASE 1 PHASE 2 PHASE 3 Sl.No PHASE 1 PHASE 2 PHASE 3 PHASE 1 PHASE 2 PHASE    3 
1 0.83 1.12 1.65 0.55 1.39 0.48 41 0.89 0.48 1.43 0.73 1.22 0.46 
2 0.72 0.8 0.64 1.01 1.01 0.28 42 0.76 0.28 0.33 0.82 0.8 0.29 
3 1.3 0.48 1.3 0.89 1.39 1.22 43 0.59 1.22 0.61 0.83 1.39 0.57 
4 1.84 0.28 0.77 0.76 1.22 0.96 44 0.86 0.8 1.68 0.72 1.01 0.48 
5 1.22 1.22 1 0.59 1.43 0.55 45 0.75 1.39 1.2 1.3 1.39 1.22 
6 1.34 0.8 1.33 0.86 1.39 1.01 46 0.88 1.01 1.23 1.84 1.53 1.3 
7 0.22 1.39 1.66 0.75 1.01 0.89 47 1 1.39 1.12 1.22 0.88 0.68 
8 0.48 1.01 1.56 0.88 1.39 0.76 48 0.27 1.22 1 1.34 1.03 1.6 
9 1.21 1.39 0.46 0.79 0.76 0.59 49 1.12 1.43 0.48 0.22 1.01 1.03 
10 1.44 1.53 0.29 0.27 0.27 0.86 50 0.8 1.39 0.28 0.48 0.13 1.38 
11 1.4 0.88 0.57 1.12 0.68 0.75 51 0.48 1.01 1.22 1.21 0.48 1.64 
12 1.5 1.03 0.48 0.8 0.9 0.88 52 0.99 1.39 0.96 1.44 0.98 0.58 
13 0.64 1.01 1.22 0.48 1.53 1 53 1.1 0.76 0.55 1.4 1.29 0.06 
14 1.33 0.13 1.3 0.99 0.88 0.27 54 0.59 0.27 1.01 1.5 1.39 1.13 
15 1.78 0.48 0.68 1.1 1.03 1.12 55 0.86 0.68 0.89 0.64 0.8 0.21 
16 1.34 0.98 1.6 0.59 1.01 0.8 56 0.75 0.9 0.76 1.33 1.1 0.32 
17 0.87 1.29 1.03 0.86 1.22 0.48 57 0.88 1.53 0.59 1.78 1.3 0.42 
18 0.41 1.39 1.38 0.75 1.23 0.99 58 1.53 0.88 0.86 1.34 1.84 0.67 
19 0.52 0.8 1.64 0.88 0.28 1.1 59 0.27 1.03 0.75 0.87 1.22 0.49 
20 0.32 1.1 0.58 1.53 1.22 1.3 60 1.12 1.01 0.88 0.41 1.34 0.28 
21 1.04 1.3 0.06 0.27 1.22 1.4 61 0.8 1.22 1 0.52 0.22 0.11 
22 1.1 1.84 1.13 1.12 1.39 1.22 62 1.23 1.23 0.27 0.32 0.48 0.91 
23 1.3 1.22 0.21 0.8 1.01 1.34 63 1.33 0.28 1.12 1.04 1.21 0.87 
24 1.18 1.34 0.32 1.23 1.39 0.22 64 0.56 1.22 0.8 1.1 1.44 0.41 
25 1.2 0.22 0.42 1.33 1.33 0.48 65 1.1 1.22 0.48 1.3 1.4 0.52 
26 1.22 0.48 0.67 0.56 1.66 1.21 66 0.59 1.39 0.99 1.18 1.5 0.32 
27 1.43 1.21 0.49 1.1 1.56 1.44 67 0.86 1.01 1.1 1.2 0.64 1.04 
28 0.33 1.44 0.28 0.59 1.22 1.4 68 0.75 1.39 1.3 1.22 1.33 1.1 
29 0.61 1.4 0.11 0.86 0.29 1.5 69 0.88 1.33 1.84 1.43 0.59 1.3 
30 1.68 1.5 0.91 0.75 0.57 0.5 70 1.53 1.66 1.22 0.33 0.86 1.18 
31 1.2 0.64 0.87 0.88 1.53 0.67 71 0.27 1.56 1.34 0.61 0.75 1.2 
32 1.23 1.33 0.41 1.53 0.27 0.62 72 1.12 1.22 0.22 1.68 0.88 1.22 
33 1.12 0.59 0.52 0.27 1.12 1.65 73 0.8 0.29 0.48 1.2 0.76 1.43 
34 1 0.86 0.32 1.12 0.8 0.64 74 0.48 0.57 1.21 1.23 0.27 1 
35 0.48 0.75 1.04 0.8 1.23 1.3 75 0.28 1.53 1.44 1.12 1.12 0.61 
36 0.28 0.88 1.1 0.48 1.33 0.77 76 1.22 0.27 1.4 1 1.2 1.68 
37 1.22 0.76 1.3 0.28 1.12 1 77 0.5 1.12 1.5 0.88 1 1.2 
38 0.96 0.27 1.18 1.22 0.8 1.33 78 1 0.8 0.5 0.28 0.28 1.23 
39 0.55 1.12 1.2 0.5 0.48 1.66 79 0.73 1.23 0.67 1.22 1.22 1.12 
40 1.01 0.8 1.22 1 0.28 1.56 80 0.82 1.33 0.62 0.96 0.8 1 
 
  
 Visual Evoked Potential(VEP) 
 
WAVE P100 latency 
 
WAVE P100 Amplitude 
 
Right Eye 
 
Left Eye 
 
Right Eye 
 
Left Eye 
Sl.No PHASE 1 PHASE-2 PHASE 3 PHASE 1 PHASE 2 PHASE 3 PHASE 1 PHASE 2 PHASE 3 PHASE 1 PHASE 2 PHASE 3 
1 96.92 95.96 99.5 96.96 93.4 99.54 7.9 8.77 8.7 7.87 6.81 6.77 
2 97.11 96.88 98 97 93.22 98.45 8.92 6.76 7 7.66 6.66 8.18 
3 96.94 97 98 97.23 93 99 7.67 8.87 7.68 7.82 8.66 6.88 
4 96.87 97.23 97.7 97.11 93.85 99.5 8.77 7.83 7.87 8 8.78 8.06 
5 96.76 97 98.65 96.84 95.23 98 7 7.78 7.62 7.83 8.87 7.78 
6 97.3 93.78 98.53 96.88 97 98.23 6.86 8.16 7.7 7.29 8.76 6.87 
7 96.96 93.7 97.24 97.12 97.05 98 6.98 8.88 7.78 8.16 8.78 8.27 
8 97 94.2 98.32 96.97 93.56 99.53 7.77 8.78 7.88 7.89 8.96 7.11 
9 96.89 98 98 96.87 95.89 96.54 7.66 8.81 6.77 7.27 9.86 7.7 
10 96.87 97 99.87 97 95.88 98.56 8.5 8.88 7 7.91 7.66 8.77 
11 96.96 95.23 99.56 97.23 94.94 99 7.78 8.78 7.6 7.86 8.69 8.8 
12 96.78 97.43 99.8 97 94.89 96.32 8.76 7.37 8.06 7.84 6.31 6.18 
13 97.21 95.21 99.87 96.23 95.5 100.56 8.4 8.31 7 6.71 7.6 7.77 
14 96.76 93 98.3 96.47 94.2 96 8.32 8.38 6.87 8.92 8.88 6.66 
15 97.29 97 98 96.75 94.87 100.87 7.66 8.88 8.27 7.79 8.8 8.87 
16 97 93 98.45 96.88 94.76 96.34 8.73 8.76 7.11 7.9 7.83 8.78 
17 96.99 93.7 99 96.87 93.6 97.68 7.9 6.86 7.7 7.88 7.88 7 
18 96.98 95 98.5 97.23 93.93 97.45 6.78 6.87 8.77 6.86 8.71 6.01 
19 97.21 96.88 98.88 96.43 93.11 97.4 7.33 7.83 8.8 7.86 7.83 6.7 
20 96.8 93.12 99 97.21 95.89 96 7.77 6 6.18 6.73 7.9 6.87 
21 97.32 97.9 97 97 94.87 97.88 7.86 6.63 7.77 7.79 8.39 8.78 
22 96.9 93.1 97.23 96.89 94.2 97.33 8 6.68 6.66 8 8.33 8.2 
23 96.87 93.7 97.89 96.59 95.78 97 7.83 6.87 8.87 7.78 8 8 
24 96.99 93.22 97.87 96.76 95.32 96 7.29 6.88 8.78 8.77 8.88 8.77 
25 97.07 93.21 99.88 96.88 95.76 97.9 8.16 6.37 8 7.7 8.5 7.77 
26 96.65 95.11 99.43 96 95.32 97.43 7.89 6.86 6.01 8 8.88 8.88 
27 97.21 97.12 99.56 97.12 95 98.88 7.27 8.66 6.7 8.1 6.98 8.62 
28 96.88 97.4 99.99 96.76 96 96.43 7.91 7.8 6.87 7.84 8.16 8.8 
29 97.03 96.23 99 96.73 96.38 96.22 7.23 7.77 6.71 7.9 6.66 8.6 
30 97 93.4 99.54 96.96 94.22 96.12 7.21 8.66 7.1 9 8.88 7.88 
31 96.96 93.22 98.45 96.75 94.8 96 7.96 8.66 8.8 8.89 8.91 7.78 
32 97.21 93 99 96.56 94.6 96.23 8.92 6.76 8 8.77 8.88 8.76 
33 97.2 93.85 99.5 97.11 94.67 96.22 6.8 8.66 7 9.63 8.88 8.77 
34 96.96 95.23 98 96.87 96.87 96.21 7.87 7.83 7.87 8.2 8.88 7.86 
35 96.99 97 98.23 96.76 96 97.89 6.93 7.78 7.62 7.83 8.97 7 
36 96.88 97.05 98 97.23 94 97 6.86 8.16 7.7 7.29 6 7.77 
37 95.99 93.56 99.53 97.4 96.65 97.97 7.9 6.88 8.26 8.16 7.66 8.27 
38 96.84 95.89 96.54 97.22 97.1 96.88 6.73 6.76 7.88 7.88 6.93 7.11 
39 96.88 95.88 98.56 96.96 93.22 98.54 7.87 6.81 6.77 7.27 6.86 7.7 
40 96.87 94.94 99 96.87 93.78 98.39 7.66 6.66 8.18 7.91 7.83 7.77 
41 96.95 94.89 96.32 97.23 93.32 97.22 7.82 8.66 6.88 7.88 6.63 8.8 
42 96.87 97.88 100.56 97.33 95.95 98.8 8 8.78 8.06 7.67 6.31 7 
43 95.98 94.2 96 97.3 95 98.46 7.83 8.87 7.78 7.9 8.77 8.7 
44 95.95 94.87 100.87 97.32 97.1 98.32 7.29 8.76 6.87 8.92 6.76 7 
45 97.11 94.76 96.34 96.89 95.95 98.68 8.16 8.78 8.27 7.67 8.87 7.68 
46 97.02 93 97.68 96.88 95 98.56 7.89 8.96 7.11 8.77 7.83 7.87 
47 96.47 93.93 97.45 96.96 95 98 7.27 9.86 7.7 7 7.78 7.62 
48 96.75 93.11 97.4 96 96.11 98.56 7.91 7.66 8.77 6.86 8.16 7.7 
49 96.88 95.89 96 96.22 96.7 97 7.86 8.69 8.8 6.98 8.88 7.78 
50 96.87 94.87 97.88 96.2 96 99.54 7.84 6.31 6.18 7.77 8.78 7.88 
51 97.21 94.2 97.33 96.87 95.12 98.54 6.71 7.6 7.77 7.66 8.81 6.77 
52 96.43 95.78 97 96.76 95.96 99.5 8.92 8.88 6.66 8.5 8.88 7 
53 97 95.32 96 97 96.88 98 7.79 8.8 8.87 7.78 8.78 7.6 
54 97 95.76 97.9 96.96 97 98 7.9 7.83 8.78 8.76 7.37 8.06 
55 96.89 95.32 97.43 97.11 97.23 97.7 7.88 7.88 7 8.4 8.31 7 
56 97.22 95 98.88 96.89 97 98.65 6.86 8.71 6.01 8.32 8.38 6.87 
57 96.76 96 96.43 96.87 93.78 98.53 7.86 7.83 6.7 7.66 8.88 8.27 
58 96.88 96.38 96.22 96.96 93.7 97.24 6.73 7.9 6.87 8.73 8.76 7.11 
59 97.16 94.22 96.12 96.78 94.2 98.32 7.79 8.39 8.78 7.9 6.86 7.7 
60 97.14 94.8 96 97.32 98 98 8 8.33 8.2 6.78 6.87 8.77 
61 96.76 94.6 96.23 96.76 97 99.87 7.78 8 8 7.33 7.83 8.8 
62 97.1 94.67 96.22 97.32 95.23 99.56 8.77 8.88 8.77 7.77 6 6.18 
63 96.96 96.87 96.21 97.22 97.43 99.8 7.7 8.5 7.77 7.86 6.63 7.77 
64 96.75 96 97.89 97 94 99.87 8 8.88 8.88 8 6.68 6.66 
65 97.21 96.5 97 96.38 93 98.3 8.1 6.98 8.62 7.83 6.87 8.87 
66 96.87 96.65 97.97 97.22 97 98 7.84 8.16 8.8 7.29 6.88 8.78 
67 96.87 97.1 96.88 96.8 93 98.45 7.9 6.66 8.6 8.16 6.37 8 
68 96.76 93.22 98.54 96.38 93.7 99 9 8.88 7.88 7.89 6.86 6.01 
69 96.97 93.78 98.39 96.67 95 98.5 7.87 8.91 7.78 7.27 8.66 6.7 
70 97 93.32 97.22 96.87 96.88 98.88 8.77 8.88 8.76 7.91 7.8 7.2 
71 96.57 95.95 98.8 96.67 93.12 99 9.63 8.88 8.77 7.23 7.77 6.71 
72 96.96 95 98.46 96.5 97.9 97 8.2 8.88 7.86 7.21 8.66 7.1 
73 96.87 97.1 98.32 96.65 93.1 97.23 7.83 8.97 7 7.96 8.66 8.8 
 
 
 
 
 
 
74 97.21 95.95 98.68 97.21 93.7 97.89 7.29 6 7.77 7.9 6.76 8 
75 95.98 95 98.56 96.88 93.22 97.87 8.16 7.66 8.27 6.8 8.66 7 
76 97.2 95 98 97 93.21 98 7.88 6.93 7.11 7.87 7.83 7.87 
77 96.93 96.11 98.56 97.99 95.11 97 7.27 6.86 7.7 7 7.78 7.62 
78 96.89 96.7 97 96.96 97.12 99.56 7.91 7.83 7.77 6.86 8.16 7.7 
79 96.88 96 99.54 97.21 97.4 99.99 7.88 6.63 8.8 7.9 7 8.26 
80 96.96 95.12 98.54 97.88 96.23 99 7.67 6.31 7 6.73 6.76 7.88 
